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Resumo 
 
A diabetes mellitus tipo 2 (DM2) é uma doença metabólica crónica que atinge proporções 
epidémicas a nível mundial. A resistência à insulina e o resultante estado de hiperglicemia 
crónica são as principais causas da desregulação do metabolismo glicídico e lipídico. As 
complicações vasculares associadas à diabetes contribuem significativamente para as elevadas 
taxas de mortalidade e morbidade observadas nesta doença. Diversas evidências científicas 
sugerem que os polifenóis da dieta, entre outros benefícios, têm a capacidade de modular a 
angiogénese e de regular certas vias metabólicas. Dado o seu potencial pleiotrópico, os 
polifenóis têm surgido como candidatos promissores para a prevenção e tratamento de 
doenças crónicas, nomeadamente a síndrome metabólica e a DM2. 
A presente tese tem como objetivo deslindar o efeito do consumo de dois polifenóis 
derivados da cerveja, o xantohumol (XM) e a 8-prenilnaringenina (8PN), num modelo animal 
de DM2 induzido pelo consumo de uma dieta hipercalórica, salientando o estudo da 
desregulação metabólica e angiogénica e nos mecanismos moleculares e vias de sinalização 
subjacentes. 
Os resultados obtidos demonstraram que o XN e a 8PN reduziram o ganho de peso 
corporal, atenuaram a hiperglicemia, melhoraram a sensibilidade à insulina e a homeostasia da 
glicose. Ambos os polifenóis melhoraram o perfil lípidico plasmático, reduzindo os 
triglicerídeos, o colesterol total, conjuntamente com uma melhoria no metabolismo lipídico. 
Tanto o XN como a 8PN ativaram a proteína cínase ativada pela 5’ adenosina monofosfato, 
inibindo a expressão da proteína de ligação ao elemento regulador do sterol (SREBP)-1c e das 
enzimas lipogénicas alvo, carboxílase da acetil-CoA e a síntase dos ácidos gordos. 
Adicionalmente, o XN e a 8PN reduziram a expressão do translocador de ácidos gordos CD36 e 
a sinalização despoletada pela ligação do fator de crescimento endotelial vascular-B ao recetor 
do fator de crescimento endotelial vascular-1, envolvida no transporte e captação de lípideos, 
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prevenindo assim a acumulação ectópica de gordura. O XN e a 8PN modularam a expressão da 
cínase 2 da frutose-6-fosfato/fosfátase 2 da frutose-2,6-bisfosfato, uma enzima glicolítica 
bifuncional cuja expressão está aumentada nas células endoteliais ativas, através da redução 
da sua expressão no rim e um aumento no ventrículo esquerdo. Este perfil de resultados vai de 
encontro aos resultados obtidos no chamado paradoxo angiogénico, evidenciado por um 
aumento da vascularização do rim e uma redução da angiogénese no ventrículo esquerdo. 
Notavelmente, o XN impediu o aumento da angiogénese renal e a 8PN ativou o processo 
angiogénico no ventrículo esquerdo, atenuando a desregulação angiogénica. 
Os resultados supramencionados ampliam o nosso conhecimento sobre a suplementação 
nutricional com polifenóis. O XN e a 8PN atenuaram a disfunção metabólica e exerceram 
efeitos distintos na angiogénese e na ativação da glicólise, de acordo com o microambiente em 
cada um dos tecidos. Esta relação entre a angiogénese e o metabolismo surge assim como um 
potencial alvo para os polifenóis, constituindo moléculas promissoras para terapias dirigidas, 
promovendo uma melhor resolução das complicações associadas à DM2. 
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 xxi 
Abstract 
 
Type 2 diabetes mellitus (T2DM) is a lifelong metabolic disorder with epidemic proportions. 
Insulin resistance and resultant hyperglycemia are the main drive forces for the deregulation 
of glucose and lipid metabolic pathways. Diabetic vascular complications significantly 
contribute for the T2DM morbidity and mortality rates. Thus, elucidating how the vascular 
system interplays with metabolic imbalances is of paramount importance. Growing evidence 
suggests that dietary polyphenols, among other benefits, are able to modulate angiogenesis 
and regulate metabolic pathways. As a result of its multifunctional properties, polyphenols 
have emerged as promising candidates for further development to treat chronic diseases 
namely metabolic syndrome and T2DM. 
This thesis aimed to unravel the effect of consumption of two polyphenols, xanthohumol 
(XN) and 8-prenylnaringenin (8PN), in high-fat diet-induced T2DM mice model, focusing on 
metabolic and angiogenic deregulation and their underlying molecular mechanisms. 
The obtained results demonstrated that XN and 8PN reduced body weight gain, mitigated 
hyperglycemia and improved insulin sensitivity and glucose homeostasis. Both polyphenols 
ameliorated plasmatic lipid profile, by reducing triglycerides and cholesterol levels together 
with an improvement of lipid metabolism. XN and 8PN activated 5’ adenosine 
monophosphate-activated protein kinase, inhibiting the expression of the sterol regulatory 
binding protein (SREBP)-1c and lipogenic target enzymes, acetyl-CoA carboxylase and fatty acid 
synthase. Moreover, XN and 8PN reduced the expression of fatty acid translocase/CD36 and 
vascular endothelial growth factor receptor-1 - vascular endothelial growth factor-B signaling, 
involved in the lipid transport and uptake, preventing ectopic lipid accumulation. XN and 8PN 
also modulated the expression of 6-phosphofructo-2-kinase-2/fructose-2,6-bisphosphatase 3, 
a glycolytic bifunctional enzyme that is up-regulated in active endothelial cells, by reducing its 
 Abstract 
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expression in kidney and increasing in left ventricle. The former results are in agreement with 
the so-called angiogenic paradox that is evidenced by an increase in kidney vascularization and 
a reduction of angiogenesis in left ventricle. Remarkably, XN prevented the increase in kidney 
angiogenesis and 8PN activated angiogenic process in left ventricle.  
The aforementioned data increase our knowledge regarding the beneficial effects of 
nutritional supplementation with polyphenols. XN and 8PN attenuated metabolic dysfunctions 
and exert distinct effects on angiogenesis and on the glycolysis activation, according to the 
distinct microenvironment within each tissue. The cross talk between angiogenesis and 
metabolism arises as a potential target for polyphenols, rendering them putative tissue 
specific-target agents that may allow a better resolution of T2DM-related complications. 
 
Keywords 
Diabetes mellitus, metabolism, angiogenesis, polyphenols  
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1. Diabetes mellitus 
1.1. Epidemiology and background of diabetes mellitus 
Diabetes mellitus (DM) is a world epidemic and growing health problem, affecting 415 
million people presently and predicted to affect more than 600 million by 2040 (Ogurtsova et 
al., 2017). According to the latest diabetes atlas from the International Diabetes Federation, 
DM was responsible for 4.6 million annually deaths worldwide, corresponding to one death 
every seven seconds. With its increasing prevalence, DM is becoming a leading cause of 
morbidity and mortality, placing a huge demand on the economic burden costs to health care 
systems and lifetime medical resources (Ogurtsova et al., 2017).  
There are four main forms of DM: gestational, maturity-onset diabetes of the young 
(MODY-1), type 1 DM (T1DM) and type 2 DM (T2DM). T2DM is the most prevalent one and 
accounts for almost 90% to 95% of diabetes cases (Gardner et al., 2012; DeFronzo et al., 2015; 
Al-Aissa et al., 2017). 
T2DM arises as a result of insulin resistance that initially is compensated by increased 
pancreatic -cells mass and insulin secretion (Gerich, 2003; Bergman, 2013). With disease 
development, pancreatic -cells mass and function progressively decline, being no longer able 
to release sufficient insulin in order to promote glucose uptake in peripheral tissues, such as 
skeletal muscle and adipose tissue. This condition is termed glucotoxicity and takes place when 
insulin-dependent tissues become desensitized to insulin, resulting in -cell dysfunction and 
chronic hyperglycemia (Ye, 2013).  
T2DM is complex and multifactorial disease. Several risk factors including obesity, physical 
inactivity, older age, genetic predisposition, high blood pressure and unfavorable lipid profile, 
namely increased cholesterol and triglycerides (TG) levels, play a causative role in the 
progression of T2DM (DeFronzo et al., 2015). Endothelial dysfunction (Sena et al., 2013), 
oxidative stress (Brownlee, 2001; Ceriello et al., 2004) and chronic inflammation (Pfutzner et 
 Introduction 
 
 
 
 2 
al., 2006) are interrelated conditions in the etiology of T2DM. T2DM associated comorbidities 
result from micro and macrovascular complications together with defects in whole body 
glucose and lipid metabolism.  
 
1.2. Diagnosis and available therapeutic approaches to type 2 diabetes 
mellitus 
According to American Diabetes Association, T2DM may be diagnosed through plasma 
glucose criteria, either the fasting plasma glucose (126 mg/dL; 7.0 mmol/L), or the 2-hour oral 
glucose tolerance test (OGTT) after a 75 g glucose load (200 mg/dL; 11.1 mmol/L) or  glycated 
hemoglobin A1c (HbA1c) criteria (HbA1c 6.5%; 48 mmol/mol) (American Diabetes, 2017). An 
early diagnosis is extremely important to delay or prevent its comorbidities (Tuomilehto et al., 
2001; Knowler et al., 2002) and early screening is crucial since almost 30% of T2DM patients 
are undiagnosed (DeFronzo et al., 2015). 
Nutritional and physical activity approaches are still the cornerstone of treatment. When a 
good glycemic control is not attained with these lifestyle modifications, glucose-lowering drugs 
are required (Tuomilehto et al., 2001; Knowler et al., 2002; Tiwari, 2015). Despite recent 
therapeutic breakthroughs, the available treatments for diabetes management are not 
completely efficient, as highlighted by the elevated mortality and morbidity rates. Presently, 
the most well established pharmacological approach in T2DM management is the use of 
glucose-lowering drugs that maintain blood glucose concentration within the normal range. 
Metformin is one of these agents, which can be used alone or in combination with other 
agents with complementary mechanisms of action, performing a specific treatment strategy 
for each diabetic patient. These therapeutic agents include sulfonylureas, to promote insulin 
secretion, thiazolidinediones (TZD) insulin-sensitizing molecules (Del Prato, 2009), as well as 
more recent therapeutic agents namely incretin-based therapies including the glucagon-like 
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peptide (GLP)-1 receptor agonist, an insulinotropic molecule poorly secreted by diabetic 
individuals, and dipeptidyl peptidase (DPP)-4 inhibitors, which prolong GLP-1 half-life (Del 
Prato, 2009; DeFronzo et al., 2015; Meece, 2017). Moreover, there is a novel therapeutic 
strategy, the sodium-glucose-linked transporter (SGLT)-2 inhibitors, which have been clinically 
used to target renal glucose absorption (Ahuja et al., 2016), promoting urinary glucose 
elimination. Management of T2DM frequently requires the combination of two or three of the 
aforementioned agents to accomplish a durable glycemic control with a specific management 
of the therapeutic strategy for each patient (Raz et al., 2013). When those pharmacological 
agents fail to normalize glycemic levels, an additional therapy with insulin is often required 
(Yacoub, 2014). Despite of the benefits, some of the current available treatments have limited 
efficacy, safety, cost-effectiveness or present unwanted side-effects (Tahrani et al., 2016). 
Therefore, it is essential to investigate the molecular signaling pathways involved in the 
pathogenesis of T2DM to develop new therapies, ideally with increased efficacy and reduced 
adverse effects.  
 
1.3. Metabolic disturbances in the pathogenesis of type 2 diabetes 
mellitus 
Liver and skeletal muscle are crucial tissues in the regulation of whole-body homeostasis 
and energy metabolism. The sustained elevations in glucose and FA blood levels observed in 
T2DM, lead to impairment of several cellular pathways and contribute to the pathogenesis of 
the disease. It is of paramount importance to fully elucidate the underlying mechanisms of this 
disease to provide guidance for T2DM prevention and treatment. 
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1.3.1. Glucose metabolism imbalance in type 2 diabetes mellitus 
The liver is the main producer of the endogenous glucose that is released into the 
circulation to be uptaken by peripheral organs. The liver is therefore a central organ in 
glycemic control, since it regulates the balance between anabolic and catabolic pathways 
(Meyer et al., 2002). In the fed state, the organism responds to the short-term disturbance in 
blood glucose levels following the intake of nutrients with a variety of systemic 
neuroendocrine responses, including the secretion of insulin by the pancreas that together 
with other hormones plays a central role in the regulation of glucose and lipid metabolism in 
the liver. In response to enhanced glucose concentration, pancreatic -cells release insulin, 
which binds to insulin receptor (IR) in the plasma membrane of insulin-sensitive cells, 
subsequently inducing the phosphorylation of selective adaptor proteins, the insulin receptor 
substrate (IRS)-1. The entire process is tightly regulated in distinct steps, both positively and 
negatively in a time-controlled manner to attain a proper signal duration and intensity (Moore 
et al., 2003; Boucher et al., 2014). After a meal, insulin elicits signaling cascades that result in 
suppression of endogenous glucose production through the inhibition of gluconeogenesis and 
glycogenolysis. Insulin also stimulates glucose utilization through increased glycolysis and 
glycogenesis. Conversely, in the fasting state, the glucose disposal is ascribed by insulin-
independent tissues (Moore et al., 2003). These effects are facilitated by an increase of 
gluconeogenic substrates including certain aminoacids, lactate, and glycerol and mediated by 
the activation of gluconeogenic enzymes, such as pyruvate carboxylase, phosphoenolpyruvate 
carboxykinase and glucose-6-phosphatase. Together with the activation of glycogenolysis, 
these processes account for approximately 90 % of glucose disposal (Bergman, 2013). 
In T2DM, however, the dysfunction in insulin signaling impairs the regulation of the liver 
glucose metabolism. For example, the insulin-induced suppression of glucose production 
through gluconeogenesis and glycogenolysis is promptly prevented. As a consequence, 
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sustained hyperglycemia and hyperinsulinemia arise and exert deleterious effects in the entire 
organism(Boden, 2011; Boucher et al., 2014).  
Blood glucose originates either from the intestine after dietary intake or from endogenous 
production in the liver and kidney and is uptaken by peripheral tissues, most notably by the 
skeletal muscle. Being the key site of glucose uptake, the skeletal muscle is therefore one of 
the main targets for the management of insulin resistance-related diseases, such as T2DM 
(Bouzakri et al., 2005).  
The glucose transporter (GLUT)-4 controls the majority of glucose transport mediated by 
insulin, while GLUT-1 mediates basal glucose transport (Saltiel et al., 2001). Together, GLUT-4 
and GLUT-1 maintain glucose blood levels within a tight physiological range. 
In the skeletal muscle, insulin controls glucose uptake by increasing the translocation of 
glucose GLUT-4 into the plasma membrane (Bouzakri et al., 2005; Thong et al., 2005). Insulin 
binds to its receptor inducing tyrosine phosphorylation of IRS-1. Therefore, IRS-1 activates 
phosphatidylinositol 3-kinase (PI3K), which in turn phosphorylates phosphatidylinositol 4,5-
bisphosphate (PIP2) in the membrane and generates phosphatidylinositol 3,4,5-trisphosphate 
(PIP3) (Thong et al., 2005). The cascade of events involving PIP3-dependent kinases, activates 
AKT protein and phosphorylates its substrate, AS160. Once activated, AS160 promotes GLUT-4 
translocation from the intracellular vesicles to cell membrane increasing the glucose uptake in 
skeletal muscle (Kramer et al., 2006). In T2DM, the protein content of GLUT-4 at the cell 
surface is markedly reduced and the insulin-stimulated glucose transport is compromised 
(Ryder et al., 2000; Bouzakri et al., 2005). This can also be attributed to decreased expression 
of AS160 in T2DM (Karlsson et al., 2005; Karlsson et al., 2006).  
Notwithstanding, the recruitment of GLUT-4 to the cell membrane to mediate the glucose 
transporter can also be promoted by insulin-independent mechanisms in response to muscular 
fibers contraction during exercise and by a nucleoside analogue, 5-aminoimidazole-4-
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carboxamide ribonucleotide (AICAR). Muscle contraction and AICAR are both activators of the 
5 adenosine monophosphate-activated protein kinase (AMPK) pathway (Kramer et al., 2006; 
Treebak et al., 2006). Once activated, AMPK facilitates the glucose transport by increasing 
AS160 and consequently GLUT-4 trafficking in skeletal muscle (Kramer et al., 2006; Treebak et 
al., 2006). Importantly, AMPK also constitutes a cellular energy sensor that acts as a major 
regulator of the whole-body energy balance by modulating tissue-specific metabolic pathways, 
rendering this protein an important therapeutic target.  
 
1.3.2. Lipid metabolism impairment in type 2 diabetes mellitus 
Impairment in insulin signaling and in glucose homeostasis also promotes and amplifies 
lipid metabolic dysfunction. Plasma free fatty acids (FFA) are elevated during fasting, and 
decreased in postprandial state, being those levels tightly controlled by insulin signaling (Ye, 
2013). FA can be obtained not only from lipid intake, but also from de novo lipogenesis. Dietary 
lipids, being mostly TG, are hydrolyzed into monoacylglycerides and FFA by the pancreatic 
lipase. Once in the intestinal epithelial cells, monoacylglycerides are re-esterified into TG, 
which are incorporated into lipoprotein particles, chylomicrons. Then, chylomicrons enter the 
bloodstream through the lymphatic system, carrying dietary TG, which are hydrolyzed in FFA 
and glycerol by the lipoprotein lipase of endothelial cell (EC), allowing their delivery to tissues. 
Next, FFA are either re-synthesized in TG that can be stored in adipose tissue intracellular lipid 
droplets, or oxidized by β-oxidation to supply energy. Insulin regulates many of the 
abovementioned processes. For instance, insulin stimulates lipoprotein lipase and TG synthesis 
in both liver and adipose tissue and inhibits hormone-sensitive lipase in adipose tissue, 
reducing lipolysis (Moore et al., 2003). 
When insulin resistance emerges, even in the presence of nutrient abundance, insulin is 
not able to suppress peripheral tissues lipolysis resulting in increased and sustained levels of 
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FFA in the bloodstream. This contributes to a metabolic impairment leading to an early T2DM 
development (Boden, 2011; Bergman, 2013; Sears et al., 2015). Moreover, low-grade chronic 
inflammation that accompanies T2DM, negatively affects insulin signaling due to adipokines 
and inflammatory mediators released by the adipose tissue (Hotamisligil, 2006). T2DM is also 
characterized by hyperlipidemia, including hypercholesterolemia and hypertriglyceridemia. 
This results from a deregulation in TG-rich lipoproteins. Increased levels of plasma TG, 
decreased high-density lipoprotein cholesterol (HDL-c), and increased levels of small dense low 
density lipoproteins (LDL) particles are commonly found in T2DM. These are accompanied by 
an elevated hepatic production and lower clearance of very low density lipoprotein (VLDL) and 
intestinal-derived chylomicrons (Howard et al., 2003; Bergman, 2013). Altogether, these 
features contribute to the lipotoxicity associated with T2DM (Bergman, 2013). FFA released by 
the adipose tissue in insulin resistance conditions, are mainly stored in the liver and skeletal 
muscle, and contribute to lipid toxicity (Ye, 2013). Furthermore, an imbalance between the 
rate of FA uptake and mitochondrial β-oxidation, de novo FA synthesis and secretion of TG may 
lead to the intracellular accumulation of TG and several intermediate metabolites of the FFA 
re-esterification pathway, such as diacylglycerol, ceramides and long-chain fatty Acyl-CoA 
(Boden, 2011). These lipid metabolites are intracellular signaling molecules that alter the 
insulin signaling and, consequently, its action (Ye, 2013; Holland et al., 2007). The increment in 
FFA uptake and β-oxidation impairs not only lipid, but also glucose metabolism. This is due to 
the inhibition of both glucose transporters and glycolysis together with the stimulation of 
gluconeogenesis as a result of the increased availability of plasma gluconeogenic substrates.  
Another important pathway increasingly investigated is the above-mentioned AMPK, a 
fundamental cornerstone of the metabolic regulation. Besides its role in the glycolytic process 
regulation, this important kinase is also a master regulator of lipid metabolism in the liver, 
skeletal muscle and adipose tissue, being an important target for metabolic diseases 
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management (Carling, 2017). Accordingly, AMPK signaling transduction pathway may underlie 
new mechanisms to control T2DM. Once activated, AMPK phosphorylates and inactivates the 
sterol regulatory element-binding transcription factor (SREBP)-1c, an important transcription 
factor involved in the synthesis and uptake of FA, acting as a key regulator of lipogenesis 
(Coughlan et al., 2014; Kim, Yang, et al., 2016).  
SREBP-1c is a key regulator of lipogenesis controlling the expression of lipogenic enzymes, 
namely acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), major biosynthetic 
enzymes for FA synthesis (Hardie et al., 1997; Zhou et al., 2001; Li et al., 2011). Lipogenesis 
encompasses the process of FA synthesis through the action of ACC and FAS and their 
subsequent esterification into TG. This process takes place mainly in the liver, but it also occurs 
in adipose tissue (Boden, 2011). The inhibition of ACC activity, through phosphorylation by 
AMPK or by downregulation of SREBP-1c, reduces the carboxylation of acetyl-CoA into 
malonyl-CoA (Figure 1.1). This molecule, resultant from the rate-limiting step of lipogenesis, is 
itself an allosteric inhibitor of carnitine palmitoyltransferase (CPT)-1, a major enzymatic 
regulator of FA oxidation. CPT-1 catalyzes the covalent binding of carnitine and long-chain fatty 
acids (LCFA) to enable LCFA to cross the mitochondrial membrane. Consequently, there is a 
stimulation of FA uptake by the mitochondria, where they undergo β-oxidation. Therefore, 
SREBP-1c expression downregulated by AMPK reduces lipogenesis and increases FA oxidation.  
The activation of AMPK has been recently proposed as an attractive pharmacological target 
to treat insulin resistance-associated diseases as T2DM (Coughlan et al., 2014; Carling, 2017; 
Ramesh et al., 2016). In fact, the mechanisms of action of several pharmacological agents used 
in the treatment of T2DM are powerful inducers of AMPK. For instance, the insulin-sensitizing 
drugs from TZD family, which are activators of peroxisome proliferator-activated receptor 
(PPAR)-γ, the hypoglycemic drug metformin, GLP-1 agonists, and DPP4 inhibitors exert their 
effects through regulation of AMPK activity, demonstrating its ability on the prevention of 
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overt T2DM (Dutta et al., 2016). Therefore, the identification of more specific and potent 
AMPK activators appears to be appellative in the treatment of T2DM.  
 
 
 
 
 
 
 
 
 
 
1.3.2.1.   Lipid uptake by peripheral tissues  
One of the main regulatory mechanisms to modulate the plasma lipid levels consists in the 
control of FFA entry and metabolism in peripheral tissues, being this process mediated by fatty 
acid transporter proteins (FATP). These transporters facilitate FA uptake into cells and 
subcellular organelles to rapidly provide substrate for metabolic demands or storage (Glatz et 
al., 2010). The hydrolysis of TG-containing lipoproteins through the lipoprotein lipases action 
releases FFA into the circulation that together with the plasma FFA bound to albumin are 
internalized into different tissues across cell surface by specific transporters (Goldberg et al., 
2009). The fatty acid translocase (FAT), also recognized as the scavenger receptor CD36, is one 
of the regulators of lipid metabolism, since it controls FA entry into the cell, as well as oxidized 
Figure 1.1 - Schematic representation of the inhibition of lipogenesis and activation of lipid oxidation mediated by 5’ 
adenosine monophosphate-activated protein kinase (AMPK). Abbreviations: acetyl-CoA carboxylase (ACC); carnitine 
palmitoyl transferase (CPT)-1; fatty acid (FA); fatty acid synthase (FAS); sterol regulatory element binding protein 
(SREBP)-1c. 
 
 Introduction 
 
 
 
 10 
LDL, oxidized phospholipids and LCFA, by mediating their movement across the cell membrane 
in several tissues (Goldberg et al., 2009). In fact, some studies performed with FAT/CD36 
knockout mice have established the requirement of this translocase to assist FA uptake, since 
this transport is blunted in the skeletal muscle, cardiac muscle and adipose tissue of these 
animals. Additionally, increased CD36 levels in liver and skeletal muscle contributes to T2DM-
related dyslipidemia (Koonen et al., 2007). Another group of lipid transporters responsible for 
the increased rate of FA uptake are the FATP. FATP are expressed in EC and promote lipid 
transport and uptake to peripheral tissues. In particular, FATP-3 and FATP-4 have recently 
been shown to be upregulated in response to vascular endothelial growth factor (VEGF)-B (Li, 
2010). Although belonging to the family of angiogenic factors, the signaling transduction 
pathway triggered by the binding between VEGF-B and its receptor, the vascular endothelial 
growth factor receptor (VEGFR)-1, and co-receptor neuropilin (NP)-1 has recently been 
associated with lipid metabolism, as represented in Figure 1.2 (Karpanen et al., 2008; Li, 2010; 
Hagberg et al., 2010).  
The inhibition of this signaling pathway has attracted considerable attention, since it may 
prevent ectopic lipid accumulation and restore insulin sensitivity in obesity and T2DM animal 
models (Carmeliet et al., 2012; Hagberg et al., 2013; Sun et al., 2014; Muhl et al., 2016). As a 
matter of fact, several studies, in both humans and animal models, have implicated the 
membrane FA transporters in the pathogenesis of diseases such as insulin resistance and 
T2DM, being considered as a promising therapeutic target to control lipid fluxes in the body in 
a tissue-specific manner (Glatz et al., 2010; Hagberg et al., 2012). 
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1.4. Vascular complications in type 2 diabetes mellitus  
Experimental and clinical evidence indicate that persistent hyperglycemia and insulin 
resistance, implicated in the development of T2DM, are major risk factors in the pathogenesis 
of vascular complications in diabetes (Ginsberg, 2000).  
The functional and structural changes in blood vessels under hyperglycemia are induced by 
endothelial dysfunction. These alterations are also attributable to increased oxidative stress 
and chronic low-grade inflammation. These are important angiogenic inducers implicated in 
T2DM pathophysiology and responsible for the development and progression of T2DM-related 
vascular complications (Giacco et al., 2010).  
Early in the course of T2DM, EC are subjected to pathological alterations in response to 
hyperglycemia. Increased inflammatory factors, including C-reactive protein, interleukins and 
Figure 1.2 - Schematic representation of vascular endothelial growth factor (VEGF) function. Vascular endothelial 
growth factor (VEGFR)-1 and VEGFR-2, the receptors for VEGF-B and VEGF-A, respectively, and neuropilin-1 (NP-1), 
the co-receptor of VEGFR-1 are expressed on the surface of endothelial cells. The binding of VEGF-A to VEGFR-2 is 
the major mediator of angiogenesis through the activation of AKT and ERK. VEGF-B signaling mediated by its binding 
to VEGFR-1 and NP-1 has recently associated to endothelial targeting of lipids to peripheral tissues, mainly to the 
upregulation of fatty acid transporter protein (FATP)-3 and FATP-4. 
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tumor necrosis factor alpha (TNF-), contribute to the chronic inflammation state. 
Additionally, high levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
lead to oxidative stress, inducing uncoupled endothelial nitric oxide synthase (eNOS), which is 
responsible for the reduced production and bioavailability of nitric oxide (NO), an important 
vasodilator. Remarkably, overexpression of adhesion molecules including intercellular 
adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1, mononuclear 
chemoactrative protein (MCP)-1, protein kinase C (PKC), leading to increased monocyte 
adhesion, as well as alterations in platelet functions and some markers of fibrinolysis, namely 
increased levels of plasminogen activator inhibitor (PAI)-1 are also associated with vascular 
modifications occurring in T2DM (Hempel et al., 1997; Festa et al., 2002; Inoguchi et al., 2000; 
Kolluru et al., 2012).  
Beyond its important role in the regulation of glucose and FA metabolism and homeostasis, 
insulin also affects the vascular endothelium, through the regulation of blood flow and 
vascular tone (Baron, 1994; Steinberg et al., 2002). The hemodynamic impact of insulin in 
blood vessels is mediated through binding to EC receptors and activation of two distinct 
pathways. The activation of PI3K pathway increases eNOS production and the subsequent 
release of NO. The resultant effect is the increase in the relaxation of surrounding smooth 
muscle cells and endothelial vasodilation, allowing a proper blood flow rate to target tissues 
(Steinberg et al., 2002). The activation of the mitogen-activated protein kinase (MAPK) 
pathway leads to endothelin (ET)-1 release, causing vasoconstriction due to binding to its 
receptor ETA on EC. The insulin-mediated balance between these effects leads to increased 
insulin diffusion, improving insulin sensitivity (Kolka et al., 2013; De Nigris et al., 2015). 
Impairment in insulin endothelial signaling affects blood flow and insulin delivery to tissues, 
independently of insulin direct effects on each tissue. Several lines of evidence described that 
the exposure to high glucose levels impairs insulin signaling in EC in vitro. EC derived from 
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obese animal models have diminished eNOS phosphorylation and reduced NO production, 
which prevents insulin-mediated vasodilation (Kubota et al., 2011; De Nigris et al., 2015).  
Additionally, raised levels of circulating FA also impair insulin-mediated vasodilation by 
reducing the activity of PI3K and AKT in vascular cells, contributing to endothelial dysfunction 
and insulin resistance in the microvasculature (Steinberg et al., 2002). 
T2DM induces a widespread damage of the endothelium leading to micro and 
macrovascular complications that affect many organs and tissues (Chawla et al., 2016). 
However, the underlying molecular mechanisms are still largely unknown. It is crucial to better 
understand the causes of T2DM-related vascular complications and unravel potential targets 
to develop therapeutic approaches aiming for their reduction or prevention. 
 
1.4.1. Endothelial cell physiology and function 
The vascular endothelium constitutes not only a selective, permeable barrier between the 
blood and tissues, but plays also,  an important role in cellular metabolism, vasomotor balance 
and vascular-tissue homeostasis (Haller, 1997; Sharma et al., 2012; Bierhansl et al., 2017). The 
endothelium is composed by a monolayer of EC that line the entire inner surface of blood 
vessels, sitting on a basement membrane and surrounded by mural cells namely pericytes or 
smooth muscle cell layers, according to the vessel’s caliber (Carmeliet, 2003). In the last 
decades, endothelium is being recognized as an active metabolic tissue with autocrine, 
paracrine and endocrine actions, mediating important physiological processes. In response to 
diverse mechanical and chemical stimuli, EC synthesize and release a large number of 
vasoactive molecules, growth factors, and mediate the transport of oxygen and nutrients, 
cytokines and hormones between the bloodstream and tissues, while removing toxic 
metabolic products. Endothelium has the capacity to ensure the maintenance of vascular tone 
by producing vasodilator or vasoconstrictor molecules to maintain normal blood flow; regulate 
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vascular smooth muscle cells and fibroblast proliferation, as well as transendothelial leucokyte 
adhesion and migration; control the production of thrombotic and fibrinolytic and platelet 
aggregation components; generate new blood vessels, among other functions (Quyyumi, 1998; 
Esper et al., 2006).  
 
1.4.2. Angiogenic process 
In physiological conditions, EC remain quiescent in the adulthood, except under specific 
situations, namely wound-healing, pregnancy, menstrual cycle and hair growth, conditions 
where neovascularization is promoted (Carmeliet et al., 2011). When EC are activated in 
response to angiogenic stimuli, they undergo vascular sprouting inducing the formation of new 
blood vessels from pre-existing ones, a process termed angiogenesis. Angiogenesis is a 
multistep process, involving a large variety of growth factors, receptors, and diverse cellular 
types that orchestrate the entire process of vessel sprouting in a coordinated and synergistic 
manner (Folkman, 1971; Duh et al., 1999; Yancopoulos et al., 2000; Ribatti et al., 2000; 
Elayappan et al., 2009; Carmeliet et al., 2011; Tykhomyrov et al., 2015). Additionally, the 
formation of blood vessels could also occur through vasculogenesis, a process that allows the 
formation of de novo blood vessels involving the recruitment, incorporation and differentiation 
of bone marrow-derived endothelial progenitor cells (BM-EPC) (Conway et al., 2001; Carmeliet, 
2003). Vasculogenesis is of major importance during embryonic development, but plays also a 
role in adulthood in different pathophysiological settings (Asahara et al., 1999; Costa et al., 
2007). 
The angiogenic process accomplishes several events including the degradation of the 
adjacent basement membrane, detachment of the surrounding pericytes and remodeling of 
the involving extracellular matrix (ECM) by the action of metalloproteinases (MMP), 
particularly MMP-2 and MMP-9. These allow local EC migration, proliferation, invasion and 
Introduction  
 
 15 
formation of tubular structures, promoting the branching and anastomosis to assemble a 
vascular structure (Carmeliet et al., 2011). Afterwards, the new vessel becomes lumenized, 
with the formation of a new basement membrane, and covered with mural cells to become 
functional (Carmeliet et al., 2011).  
The EC phenotype changes in the sequential stages of vessel growth. In response to 
stimuli, EC switch from a quiescent state to a highly migratory tip cells phenotype. Tip cells are 
at the forefront to guide the extending sprout through the ECM. The activation of pro-
angiogenic signaling programs in tip cells, induce the expression of delta-like 4 (DII4), that acts 
in neighboring cells through binding the Notch receptor (De Smet et al., 2009; Potente et al., 
2011). Once activated, Notch signaling inhibits a tip cell phenotype in these adjacent cells 
yielding them to adopt a proliferative stalk-like phenotype, responsible for branch elongation. 
These EC could dynamically switch between both tip and stalk phenotypes during vessel 
growth, in a competitive and dynamic manner, to reach the tip position (Jakobsson et al., 
2010; Potente et al., 2011). Phalange cells line the established perfused vessels and acquire a 
quiescent state (Hellstrom et al., 2007; Yoon et al., 2014). The delicate balance between the 
dynamic process involving tip, stalk and phalanx EC phenotype via cell-to-cell signaling is 
necessary during vascular formation (Gerhardt et al., 2003; Hellstrom et al., 2007; De Smet et 
al., 2009).  
The angiogenic process is orchestrated by an intricate balance between pro-angiogenic 
factors such as, VEGF-A, placental growth factor (PIGF), fibroblast growth factor (FGF), 
transforming growth factor beta (TGF-), hepatocyte growth factor (HGF), platelet derived 
growth factor (PDGF), platelet derived-endothelial growth factor (PD-ECGF) and angiopoietins, 
and anti-angiogenic molecules including pigment epithelium-derived factor (PEDF), 
thrombospondin-1 (TSP)-1, PAI-1, angiostatin and endostatin (Yancopoulos et al., 2000; Presta 
et al., 2005; Ferrara et al., 2005; Folkman, 2007).  
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Despite the contribution of the aforementioned promoters to vessel growth, there is 
consensus that VEGF-A is the most powerful pro-angiogenic factor and it is secreted by a wide 
variety of cells, activating EC (Ferrara et al., 2003). VEGF-A stimulates EC through binding to 
VEGFR-2, conveying signal transduction pathways that regulate distinct cellular responses 
related to vascular physiology, metabolism and homeostasis. The VEGF family in mammals 
comprises five structurally-related members: VEFG-A to VEGF-D and PlGF, that exert its 
biological functions through binding to VEGFR-1, VEGFR-2 and VEGFR-3 (Rahimi, 2006; Koch et 
al., 2012). VEGF-A binds and activates VEGFR-1 and VEGFR-2 on EC surface. Although VEGF-A 
has more affinity to VEGFR-1, the intracellular signal transduction is weak (Robinson et al., 
2001). The potent pro-angiogenic effect of VEGF-A is mediated by its binding to VEGFR-2, 
triggering dimerization and transautophosphorylation of cytoplasmatic tyrosine residues 
associated with distinct steps of the angiogenic process and constitutes a major regulator of 
vessel physiology (Ferrara et al., 2005; Koch et al., 2012). VEGF-A stimulates EC permeability 
and survival through the activation of PI3K activity, with subsequent increase in AKT and eNOS. 
Additionally, it potentiates the activation of PKC and mediates the activation of extracellular 
signal-regulated kinases (ERK)1/2, a pathway responsible for EC proliferation, migration, 
tubulogenesis and leukocyte adhesion (Meadows et al., 2001; Zachary et al., 2001; Fearnley et 
al., 2014). Current knowledge about the role of VEGF-B on angiogenesis has led to 
controversial results, since some studies demonstrated a pro-angiogenic effect, whereas 
others observed an anti-angiogenic potential in several experimental models (Silvestre et al., 
2003; Kearney et al., 2004; Li et al., 2009). VEGF-B and PlGF bind to the same receptor, VEGFR-
1 and NP-1. Surprisingly, however, it has been postulated that VEGF-B activates a signaling 
cascade related to lipid metabolism. PlGF signaling is involved in inflammation and 
pathological angiogenesis and also in embryogenesis (De Falco, 2012). VEGF-C and VEGF-D 
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bind preferentially to VEGFR-3 and VEGF-D and its expression in the is primarily on lymphatic 
vessels, regulating lymphandothelial function (Cebe-Suarez et al., 2006; Koch et al., 2012). 
When a major disequilibrium between angiogenic stimulators and inhibitors arises, the 
angiogenic process becomes deregulated and is associated with multiple diseases (Folkman, 
2007). Excessive angiogenesis is implicated in cancer and several chronic diseases namely, 
atherosclerosis, diabetic retinopathy, rheumatoid arthritis and age-related macular 
degeneration. On the contrary, insufficient vessel growth is found in chronic non-healing 
wounds, ulcers, ischemic heart disease and other pathological situations (Carmeliet et al., 
2011). In the pathogenesis of T2DM, angiogenesis plays an ambiguous role, with increased 
vascularization in certain organs and reduced in others, in the same organism, in the so-called 
angiogenic paradox.  
 
1.4.3. Angiogenic paradox in diabetes mellitus 
T2DM is characterized by endothelial dysfunction, resulting in increased inflammation and 
oxidative stress, impaired vasodilation and perfusion due to the imbalance in VEGF and NO 
production, and a pro-thrombotic state (Bierhansl et al., 2017; Shi et al., 2017). The 
heterogeneity of T2DM-related vascular complications is partially explained by the nature of 
micro- and macrovascular beds, the structure of the endothelium in each tissue, and the local 
microenvironment surrounding vessels (Waltenberger, 2007). Microvascular disease affects 
small vessels, including small resistance arteries, venules and capillaries and clinically results in 
retinopathy, nephropathy and neuropathy that contribute to blindness, kidney failure, limb 
amputations and nerve damage (Khazaei, 2011; Cheng et al., 2015; Bierhansl et al., 2017). 
Macrovascular disease occurs in large vessels, often leading to atherosclerosis, 
thromboembolism, cerebrovascular disease, ischemic heart disease, peripheral artery disease 
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and stroke. These vascular complications are the leading cause of morbidity and mortality 
among patients T2DM (Domingueti et al., 2016; Bierhansl et al., 2017). 
Chronic hyperglycemia can lead to long-term tissue damage. Together with 
hyperinsulinemia, glycation and lipoxidation end products, oxidative stress, low-grade 
inflammation and hypoxia, it potentiates vascular complications associated with T2DM. The 
exposure of EC to abnormal levels of growth factors, pro-inflammatory cytokines and ROS 
during the course of T2DM, clearly impairs endothelial signaling pathways, affecting the 
balance between kinases and phosphatases that alter protein function. These alterations are 
accompanied by increased ECM synthesis and basal membrane thickness, which affect blood 
flow and vessel permeability. T2DM impairs the nutritive primary function of EC since the 
vasculature loses the ability to grow and regress in accordance to tissue metabolic demands 
(Soares et al., 2009; Chawla et al., 2016).  
As mentioned, in T2DM the angiogenic process is affected in a tissue-dependent manner. 
Excessive angiogenesis occurs in organs, namely kidney and retina, whereas a marked 
decrease in neovessel formation is found in coronary artery disease and peripheral vascular 
disease. Patients with diabetic retinopathy exhibit elevated vitreous and aqueous VEGF-A and 
hypoxia inducible factor (HIF)-1 levels, together with VEGFR-2 overexpression, which ends up 
in increased neovessel formation (Betts-Obregon et al., 2016). However, the newly formed 
vessels have less pericyte coverage, are leaky and dysfunctional. This leads to hemorrhages, 
exudates and edema and enhances diabetic retinopathy, a major cause of blindness (Betts-
Obregon et al., 2016; Grigsby et al., 2016). Regarding diabetic nephropathy, diabetic mice 
exhibit higher renal VEGF-A levels and VEGFR-2 expression when compared to healthy 
controls. Additionally, diabetic animals exhibited overexpression of ECM components in renal 
cortex and glomeruli and increased permeability to macromolecules (Chen et al., 2008). 
Conversely, reduced neovascularization is also a feature of T2DM. Several studies reported a 
Introduction  
 
 19 
marked decrease in VEGF-A levels in diabetic dermal wounds and diabetic foot ulcers (Lerman 
et al., 2003). Since angiogenesis is critical to guarantee normal resolution of wound healing, 
the reduction in vessel formation and VEGF-A levels, decreases the recruitment of several cell 
types to the injury site, which compromises the re-epithelization and collagen deposition. 
Altogether this promotes the occurrence of chronic, non-healing ulcers that frequently result 
in amputations (Bao et al., 2009). In a study conducted with diabetic patients with coronary 
heart disease, high cardiac VEGF-A levels but reduced VEGFR-2 expression was found, 
preventing efficient angiogenic signaling (Sasso et al., 2005). Other studies reported that the 
myocardium of diabetic patients exhibits reduced levels of both VEGF-A and its receptor 
VEGFR-2 as well as the downstream effectors AKT and eNOS, together with higher angiostatin 
production (Chou et al., 2002; Weihrauch et al., 2004; Sasso et al., 2005).  This deregulation 
favoring the anti-angiogenic in detriment of pro-angiogenic factors, leads to an insufficient 
angiogenesis in diabetic patients with ischemic cardiomyopathy.  
Despite several experimental and clinical studies that have addressed the angiogenic 
paradox, the underlying molecular mechanisms remain to be explained. The present main 
challenge in T2DM consists in the discovery of tissue-specific therapeutic approaches.  
  
1.4.4. Endothelial cell metabolism as a promising target for vascular disease 
The EC metabolic pathways and their regulation during vessel formation and function have 
only been recognized in the last few years. The in-depth understanding of EC metabolism is 
crucial to identify potential targets to treat vascular complications.  
Tip cells essentially rely on glycolysis to produce ATP for rapid generation of energy to 
migrate and proliferate towards avascular areas, in response to angiogenic stimuli (De Bock et 
al., 2013; Eichmann et al., 2013). In avascular areas, oxygen becomes limiting. In order to 
compensate for the oxygen deficit, EC are activated by HIF-1 and stimulate several 
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angiogenic factors, glucose transporters and glycolytic enzymes, stimulating the glycolytic 
pathway (Obach et al., 2004; Cantelmo et al., 2015). The EC glucose uptake is mediated 
through the activation of the PI3K-AKT pathway, which induces cell surface expression of 
glucose transporters, mainly GLUT-1 (Yeh et al., 2008). In EC, glucose is metabolized into 
pyruvate through the glycolytic pathway (De Bock et al., 2013). It has been reported that the 6-
phosphofructo-2-kinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) enzyme expression is 
induced by hypoxia in several cell lines (Atsumi et al., 2005; Payne et al., 2005) and animal 
models (Minchenko et al., 2003). PFKFB3 is a bifunctional enzyme abundant in EC, that plays 
an important role in ensuring the high glycolytic flux, essential for vessel growth (De Bock et 
al., 2013; Eichmann et al., 2013; Eelen et al., 2013; Zecchin et al., 2015; Smith et al., 2015). This 
enzyme contains both kinase and phosphatase activities but, under hypoxia conditions, its 
kinase activity is more active than the phosphatase one, favoring the fructose-2,6-
bisphosphate (F-2,6-BP) synthesis. F-2,6-BP is the most potent allosteric activator of the key 
glycolytic enzyme 6-phosphofructo-1-kinase (PFK-1), and thereby sustains a high glycolytic rate 
(Van Schaftingen et al., 1982; Eichmann et al., 2013). Recently, Schoors and collaborators 
demonstrated the therapeutic potential of endothelial PFKFB3 regulation (Schoors, Cantelmo, 
et al., 2014). The authors used a small molecule 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one 
(3PO) to inhibit PFKFB3 in vitro and silencing PFKFB3 in vivo and the resultant effect was a 30-
40% decrease in the glycolytic pathway. Consequently, there was a partial and transient 
glycolysis inhibition, sufficient to reduce EC migration, proliferation and sprouting (Schoors, De 
Bock, et al., 2014; Zecchin et al., 2015). Additionally, experiments in mice and zebrafish  with a 
genetic deletion of Pfkfb3, showed a reduction in EC sprouting, rendering  a stalk phenotype 
(De Bock et al., 2013; Schoors, Cantelmo, et al., 2014). These data suggest that anti-angiogenic 
therapies could be based on the inhibition of this metabolic target, starving pathological 
vessels. In contrary, if there is overexpression of PFKFB3 in stalk EC, they switch its angiogenic 
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properties acquiring a tip cell phenotype (De Bock et al., 2013; Eelen et al., 2013). Thus, 
glycolysis is induced by PFKFB3 overexpression and drives angiogenesis, independently of 
VEGF-A signaling, being sufficient to overcome Notch signaling that would normally promote a 
stalk phenotype (Schoors, Cantelmo, et al., 2014). Hence, PFKFB3 expression appears as an 
important regulator of the endothelial phenotype, postulating that a metabolic switch induces 
the angiogenic switch.  
Moreover, recent research demonstrates the role of endothelium in regulating FA 
transport and uptake for internal use or to fuel perivascular cells (Hagberg et al., 2010). As 
mentioned above, the best characterized endothelial FA transporters are CD36 and members 
of the FATP family (Kazantzis et al., 2012). Thus, targeting these lipid transporters is a 
promising therapeutic strategy for the management T2DM vascular complications. 
Interestingly, as already reported, emerging research revealed the interesting role of VEGF-
B signaling in the endothelial uptake of circulating FA, through the stimulation of VEGFR-1 and 
co-receptor NP-1. VEGFR-1 activation enhances the expression of FATP-3 and FATP-4. Herein, 
the activation of these transporters in EC promotes endothelial lipid uptake and FA delivery in 
peripheral tissues, to be metabolized (Hagberg et al., 2010; Eichmann et al., 2013). Recently, it 
was demonstrated that EC treated with VEGF-B increase gene and protein expression of 
several FATP without affecting the expression of FAT/CD36 or fatty acid binding protein (FABP) 
(Hagberg et al., 2010). Studies performed in mice fed with HFD and treated with antibodies 
against VEGF-B showed improvements in insulin sensitivity and glucose tolerance due to 
decreased endothelial-to-tissues transport of FA. (Hagberg et al., 2010; Carmeliet et al., 2012; 
Hagberg et al., 2012). These findings are of special importance since the reduction of VEGFB-
VEGFR1 signaling could decrease ectopic lipid deposition, a major contributor for the 
pathogenesis of T2DM. 
 Introduction 
 
 
 
 22 
Angiogenesis seems to be coordinated not only by the well-known angiogenic factors but 
also by metabolic mediators. Given its pivotal location and function, the endothelium has vital 
roles in non-vascular systems regulating a wide variety of cell types and tissues, highlighting its 
therapeutic potential. Metabolism appears therefore as an interesting target to modify EC 
structure and function, particularly in diseases such T2DM in which angiogenesis is 
compromised. Therapeutic interventions focused on the modulation of the VEGF-VEGFR axis 
and EC metabolic molecules, could lead to a better management and improvement of T2DM 
outcomes. 
 
2. Polyphenols 
2.1. Polyphenols in plants and nutritional bioavailability  
Polyphenols are phytochemicals and secondary metabolites of plants, abundant in fruits, 
vegetables, cacao, and beverages, such as wine, tea and beer, widely consumed in Western 
diets. As secondary metabolites, polyphenols are very important to plant defense mechanisms 
and to its survival, propagation and development, contributing to their colors, aroma, flavor, 
bitterness, astringency and antioxidant protection (Manach et al., 2004; Stevenson et al., 
2007).  
Thus far, thousands of polyphenols have been identified with distinct chemical structures. 
They are mainly characterized by the presence of several hydroxyl groups covalently linked to 
an aromatic ring (Manach et al., 2004). Structural differences of polyphenols result in distinct 
bioavailability due to differences in digestion, gut absorption and rate of metabolism leading 
to diverse biological activities and therapeutic value. The polyphenol content and chemical 
structure are distinct according to the climatic conditions, food sources, some of which contain 
a wide mixture of polyphenols (Manach et al., 2004). However, it has been estimated that the 
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average dietary intake of these compounds is about 1 g per day, depending on nutritional 
habits and preferences (Scalbert et al., 2000). 
 
2.2. Health promoting properties 
During the last decades, epidemiological and experimental studies have revealed health 
beneficial effects associated with the consumption of polyphenols (Stevenson et al., 2007; 
Magalhães et al., 2009). through the regulation of various biochemical, physiological and 
endocrinological pathways, highlighting their potential in maintaining health and preventing 
disease (Fraga et al., 2010). 
In general, beneficial effects of polyphenols in human’s health have been associated to 
their antioxidant activity as free radical scavengers (Stevenson et al., 2007). However, they also 
seem to have pleiotropic effects on biological systems, modulating signaling transduction, and 
gene expression (Santangelo et al., 2007; Fraga et al., 2010). Thus, polyphenols induce, 
simultaneously, more than one biological effect with distinct but sometimes overlapping 
mechanisms of action.  
Based on several epidemiological findings, animal studies and clinical trials, polyphenols 
have been implicated in improving glucose homeostasis, reducing insulin resistance and 
decreasing inflammation (Santangelo et al., 2007). This is particularly important when 
considering that obesity and metabolic diseases are associated with increased insulin 
resistance, endothelial dysfunction and dyslipidemia. These metabolic derangements are, in 
turn, associated with a higher risk for developing hypertension and cardiovascular diseases. 
Therefore, there is clear evidence to support the role of polyphenols as potential agents for 
the prevention and treatment of T2DM and its metabolic-associated abnormalities.   
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2.3. Xanthohumol and 8-prenylnaringenin in hops and beer 
The female hop plant (Humulus lupulus L.) is a plant of the Cannabacaea family that 
contains large amounts of relevant secondary metabolites. Its flowers, hops, have been used 
since ancient times for traditional medicinal purpose. These include treatment of sleep 
disturbances, depression and management of menopausal symptoms. Nowadays, due to an 
increase of beer consumption worldwide, especially among young people, hops are almost 
exclusively used to confer aroma and bitterness in the beer production industry. (Zanoli et al., 
2008). 
Hops and beer contain several polyphenols that have been studied by various research 
groups. The chalcone xanthohumol (XN) is the main hops prenylflavonoid. Its content varies 
from 0.2 to 1.1% (dry weight) in hop cones (Stevens et al., 1999). A small amount of 
desmethylxanthohumol (DMX) can also be found in lupulin glands of hops. Hops chalcones (XN 
and DMX) may be accompanied by other prenylated flavanones such as isoxanthohumol (IXN), 
8-prenylnaringenin (8PN) and 6-prenylnaringenin (6PN). As represented in Figure 2.1, XN is 
mainly converted into IXN, due to thermal isomerization during extraction of hop cones and 
wort boiling in beer process. However, hops’ DMX has two free hydroxyl groups that can 
participate in cyclization and ring closure, leading to two flavanones 8PN and 6PN. 8PN, a 
potent phytoestrogen, can also be formed in vivo by O-demethylation of IXN by liver 
microsomes and intestinal bacteria metabolism (Stevens et al., 1999; Yilmazer et al., 2001; 
Nikolic et al., 2005). 
 
Introduction  
 
 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4. XN and 8PN as health-promoting compounds 
Beer is an unique source of hop polyphenols in human diet and XN has received special 
attention, due to its antioxidant behavior and potential biological properties that may have 
therapeutic interest (Zanoli et al., 2008; Magalhães et al., 2009). Several studies suggest that 
the consumption of XN is associated with lower risk of development and progression of 
oxidative stress-related diseases, such as chronic diseases (Nozawa, 2005; Costa et al., 2013; 
Legette et al., 2013; Liu et al., 2014). It has also been reported that XN possesses a broad-
spectrum of anti-infection activity against several microorganisms (antifungal, antibacterial, 
antiviral and antimalarial) (Gerhauser, 2005b; Nowakowska, 2007; Zanoli et al., 2008). 
Figure 2.1 - Chemical structures of hop prenylflavonoids. By thermal isomerization, the chalcones xanthohumol (XN) 
and desmethylxanthohumol (DMX) are converted into the flavanones isoxanthohumol (IXN) and 8-prenylnaringenin 
(8-PN), respectively.  8-PN could also be formed by O-demethylation of IXN in vivo. 
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Additionally, it has significant anti-proliferative and cancer chemopreventive effects, through 
regulation of mechanisms involved in carcinogenesis, induction of apoptosis and due to its 
anti-angiogenic potential (Stevens et al., 2004; Gerhauser, 2005a; Zanoli et al., 2008; Monteiro 
et al., 2008; Negrão et al., 2010; Negrão et al., 2012; Costa et al., 2013).  XN also prevents 
atherosclerosis, by inhibiting cholesterol accumulation in atherogenic regions (Hirata et al., 
2012; Doddapattar et al., 2013). XN has strong in vitro antioxidant properties and improves 
plasma antioxidant capacity (Ghiselli et al., 2000). This remarkable antioxidant behavior of XN 
and other prenylated hop flavonoids is very important in the context of T2DM, since they 
readily scavenge ROS and RNS , therefore preventing LDL oxidation and protecting blood 
platelets from oxidative and/or nitrative modifications, thus preventing vascular thrombosis 
and inflammation (Olas et al., 2011). Experimental data has shown that XN exerts anti-obesity 
activities through the inhibition of pre-adipocyte differentiation and adipogenesis. This is 
achieved by decreasing  PPAR and FABP expression in adipocytes, as well as its lipid content 
(Yang et al., 2007; Kiyofuji et al., 2014). 
We have previously shown that beer polyphenols, particularly XN and 8PN, exert distinct 
effects on angiogenesis, in EC cultures and animal models. It was observed that XN exerted 
anti-angiogenic effects, whereas 8PN stimulated angiogenesis (Negrão et al., 2010; Negrão et 
al., 2012). Using a T1DM rat model, we demonstrated that the intake of XN-fortified 
beverages, led to a reduction of angiogenesis, serum inflammatory markers and tissue 
oxidative damage together with the enhancement of endogenous antioxidant defenses (Costa 
et al., 2013). The antidiabetic effect of XN has also been recently investigated. Recent studies 
revealed that the ingestion of a XN-rich extract by diet-induced obese rats resulted in 
reduction of body weight gain and decreased liver and plasma TG levels (Yui et al., 2014). An 
interesting study indicated that XN-fed diabetic mice had decreased plasma glucose and TG 
levels, reduced adipose tissue mass and increased levels of adiponectin (Nozawa, 2005). 
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Moreover, Legette and colleagues reported that the XN oral administration ameliorates 
glucose metabolism and reduces body weight in obese rats (Legette et al., 2013). The 
mechanisms sustaining the aforementioned antidiabetic activities of  XN include the selective 
inhibition of α-glucosidase, the decrease of intestinal carbohydrate digestion and its 
absorption (Liu et al., 2014), the inhibition of intestinal FA absorption,  the regulation of 
hepatic FA metabolism, (Yui et al., 2014) and its action as a ligand of the farnesoid X receptor, 
involved in lipid and lipoprotein metabolism (Nozawa, 2005). Altogether, these findings clearly 
suggest that XN is a promising molecule to treat obesity and T2DM-metabolic disturbances.  
Compelling evidence suggests that dietary phytoestrogens, namely isoflavones from cocoa 
are able to improve insulin sensitivity in diabetic postmenopausal woman, suggesting a 
positive effect in diabetes prevention (Curtis et al., 2012). Over the years, it has been 
suggested that hops have a powerful estrogenic activity mainly attributable to 8PN.  Numerous 
in vitro and in vivo studies in ovariectomised rats and postmenopausal women, have been 
conducted to clarify the estrogenicity potential of beer prenylflavonoids. In the breast cancer 
cell line MCF-7 and in the rat mammary gland, 8PN stimulates cell proliferation by binding to 
the estrogen receptor (ER), mainly through interaction with ER, responsible for the 
proliferative effects of estrogens (Helle et al., 2014). In accordance, 8PN demonstrates higher 
affinity to ER when compared to ER, that counteracts the ER-dependent responses, 
triggering a greater estrogenic activity when compared to other estrogenic compounds, such 
as coumestrol and genistein albeit with a lesser potency than the natural ligand 17-estradiol 
(Milligan et al., 1999; Schaefer et al., 2003; Overk et al., 2008). The pharmacokinetics and 
metabolism of 8PN have been investigated in animal models and then confirmed in human 
studies. In these trials, 8PN was orally administered to postmenopausal women, exerting 
systemic endocrine effects  (Rad et al., 2006). Estrogens are important regulators not only in 
the reproductive system but also in other target tissues including cardiovascular and central 
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nervous systems and bones (Cos et al., 2003). Furthermore, 8PN signaling mediated by ERα 
was shown to be more selective than 17-estradiol in bone tissue (Rad et al., 2006; Luo et al., 
2014). These results suggest that 8PN could be used as alternative estrogen replacement 
therapy in menopause, being also promising to ameliorate osteoporosis. 8PN could be used in 
nutrition or pharmacological industries as a natural selective ER modulator (Simons et al., 
2012). 
A previous study performed in ovariectomized rats demonstrated the beneficial effects of 
8PN in lipid metabolism. The dietary intake of 8PN led to decreased LDL levels and an overall 
anti-atherosclerotic effect, suggesting its potential role in cardiovascular disease (Bottner et 
al., 2008). Nevertheless, little is known about the effect of 8PN in lipid metabolism and 
metabolic diseases, such as T2DM. Furthermore, the apparent antagonic effect of XN and 8PN 
in angiogenesis, a deregulated process in T2DM, deserves to be explored. Accordingly, 
nutritional or pharmacological supplementation with these polyphenols, which distinctly affect 
the vasculature and metabolism, may potentially ameliorate T2DM-related vascular 
complications by targeting the “angiogenic paradox”. 
XN and 8PN effects deserve to be better studied as they may be very promising 
compounds with great benefit for public health, particularly when prevention of highly 
prevalent diseases is mandatory. 
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Scope of the thesis 
 
The incidence of T2DM has dramatically increased worldwide over the past 
decades. T2DM-related metabolic and vascular comorbidities have been postulated to 
be the major causes for the increased morbidity and health care costs associated with 
this disease. Intensive efforts have been done to develop novel strategies to counteract 
the T2DM comorbidities. We propose to explore the use of dietary natural compounds 
as a promising approach to this problem. Two distinct polyphenols have been 
investigated due to their interesting opposing effects in angiogenesis. XN has been 
recently reported to be a promising molecule in the treatment of metabolic diseases, 
given its effects in diabetic-associated metabolic disturbances. Yet, relatively little is 
known about the potential benefits and risks of its chronic consumption and even less 
is known about its metabolite, 8PN, as well as about the underlying mechanisms of 
action of both polyphenols in vivo. Herein, the present work aims to unravel the 
potential modulatory effect of XN and 8PN on T2DM-related complications in a high fat 
diet (HFD)-induced diabetes animal model. The research presented here focuses on 
the metabolic and angiogenic signaling pathways that are deregulated in T2DM and 
highlights the potential preventive role of polyphenols’ consumption. The specific aims 
are:  
• To evaluate the effect of XN and 8PN consumption on glucose and lipid 
metabolic deregulations in a T2DM animal model, by studying metabolic 
pathways in liver and skeletal muscle; 
• To examine the effect of XN and 8PN consumption on angiogenic pathways, in 
the kidney and left ventricle, tissues associated with the angiogenic paradox, in 
a HFD-induced T2DM animal model. This can potentially elucidate the role of 
these polyphenols as tissue-specific vascular modulators in T2DM.
  
 
 
  
 
 
 
. 
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3. Xanthohumol and 8-prenylnaringenin ameliorate diabetic-
related metabolic dysfunctions in mice 
 
3.1. Background 
The prevalence of obesity and T2DM has dramatically increased over the past decades, and 
their associated metabolic complications are considered a major health problem affecting 
more than 400 million adults worldwide (Shaw et al., 2010). As a hallmark sign of T2DM, 
hyperglycemia is one of the main causes of glucose control and lipid metabolism impairments, 
early outcomes of insulin resistance. The available treatment strategies for diabetes 
management are not completely efficient, as highlighted by the markedly increased morbidity 
and mortality rates in diabetic patients. According to this, lifestyle modification and improved 
pharmacological preventive and therapeutic approaches for T2DM are needed. In recent years,  
studies using  novel pharmacological treatments and functional foods to regulate energy 
metabolism have been conducted in order to control T2DM (Tiwari, 2015). Growing evidence 
indicates that polyphenols, apart from antioxidant activity, possess health-promoting 
properties associated with the prevention and therapeutic approaches being associated with 
low risk for the development and progression of chronic diseases namely diabetes and 
cardiovascular disease (Rains et al., 2011; van Dam et al., 2013). Several epidemiologic studies 
suggest that a polyphenol-enriched diet is an important strategy to prevent obesity and 
related chronic diseases namely T2DM. Both XN and 8PN beer-derived polyphenols have been 
shown to possess interesting biological effects namely antidiabetic, anti-inflammatory and 
anticarcinogenic (Stevens et al., 2004; Gerhauser et al., 2005; Zanoli et al., 2008; Miranda et 
al., 2016b). However, the underlying mechanisms of metabolic action of XN and 8PN in lipid 
and glucose pathways have not been thoroughly investigated.  
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The present study aims to identify the pathways involved in the metabolic 
disarrangements and to address the putative role of polyphenols in counteracting the 
development of T2DM. Our attention has focused in both liver and skeletal muscle, important 
metabolic tissues in the regulation of energy metabolism and body homeostasis. AMPK is a key 
metabolic regulator present in both tissues and plays an important role in the control of 
glucose and lipid metabolism (Hardie, 2013; Ramesh et al., 2016). Evidence suggests that a 
decrease in AMPK activity may cause metabolic disorders. Thus, modulation of this regulatory 
enzyme could be a promising target for treating metabolic disturbances. Once activated, AMPK 
suppresses the expression of SREBP-1c, an important transcription factor involved in the FA 
biosynthesis and lipid uptake (Lopez et al., 1996; Magana et al., 1996; Goldstein et al., 2006; 
Sato, 2010; Xiao et al., 2013). SREBP-1c primarily regulates lipogenic enzymes such as ACC and 
FAS, which in turn inhibits lipid biosynthesis and stimulates FA -oxidation (Horton et al., 2002; 
Abu-Elheiga et al., 2005; Hardie, 2013). Hence, AMPK-dependent phosphorylation of SREBP-1c 
might be a potential approach to treat lipid disarrangements as in T2DM and other metabolic 
diseases (Li et al., 2011; Xiao et al., 2013; Choi et al., 2014).  
FFA are taken up through specific transporter proteins, being the CD36 the best 
characterized FAT (Goldberg et al., 2009). CD36 was linked to lipid metabolism accounting for 
the increased rate of FA transport into several tissues of HFD-fed animals (Goldberg et al., 
2009; Su et al., 2009). Increased expression of hepatic and muscle CD36 protein in response to 
a HFD is sufficient to exacerbate TG storage and secretion, contributing to the dyslipidemia 
associated with T2DM development (Kelley et al., 2001; Goldberg et al., 2009; Su et al., 2009). 
Some studies have demonstrated that polyphenols down-regulate CD36 gene expression 
displaying lipid-lowering effect (Aoun et al., 2011). However, the potential of XN and 8PN in 
this transporter expression has never been addressed. Hagberg and colleagues have recently 
proposed the involvement of VEGFR-1 and its ligand, VEGF-B, in the lipid transport and uptake 
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from EC to tissues (Hagberg et al., 2010; Hagberg et al., 2012).  Moreover, it is well-
documented that the deregulation on glucose uptake by skeletal muscle in T2DM  is primarily 
modulated by insulin-sensitive GLUT-4 through PI3K/AKT pathway (Klip, 2009). In order to 
understand the involvement of polyphenol consumption in glucose uptake, AS160, an AKT 
substrate was assessed in the present work as a mediator of the GLUT-4 translocation. 
Furthermore, the expression of an important glycolytic regulator also involved in insulin 
signaling, PFKFB3 was also assessed in our study. PFKFB3 regulates glycolysis through the 
production of Fru-2,6-BP, which is a potent allosteric activator of PFK-1, the glycolysis rate-
limiting step (Domenech et al., 2015; Trefely et al., 2015). A study conducted by Trefely and co-
workers demonstrated that the in vitro inhibition of PFKFB3 suppressed insulin-stimulated 
glucose uptake and GLUT-4 translocation, impairing insulin signaling and exacerbating insulin 
resistance (Trefely et al., 2015).  
Herein, we evaluated the diabetic-preventive effect of XN and 8PN using an HFD-induced 
diabetic mice model by exploring the molecular mechanisms associated with diabetic 
metabolic dysfunction.  
 
3.2. Materials and methods 
3.2.1. Animals and experimental mice treatment  
Thirty 6-week old male C57Bl/6 mice (Charles-River, Spain) were randomly divided into 5 
experimental groups (n=6), and fed ad libitum with: Standard diet (C); HFD (obtained from 
Research diets, #D12451, New Jersey, USA) (DM); HFD plus 0.1 % ethanol in drink water (DM-
Ethanol); HFD and 10 mg/L XN (Hopsteiner, Germany) in 0.1 % ethanol (DM-XN); HFD plus 10 
mg/L 8PN in 0.1 % ethanol (DM-8PN) during 20 weeks. The 8PN was synthetized according to 
previously described procedures (Zierau et al., 2002). This mouse strain is prone to develop 
T2DM under HFD ingestion, displaying significant dyslipidemia, insulin resistance and glucose 
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intolerance, as demonstrated by others (Blake et al., 2014). During the treatment period, body 
weight and glycemia were monitored weekly, food and beverage intake were controlled every 
two days. Beverages were renewed every two days and were kept in dark bottles to avoid 
compound degradation. After 20 weeks of treatment, animals were then sacrificed and 
skeletal muscle and liver were frozen at -80 ºC for molecular analyses or fixed in 10% neutral-
buffered formalin, dehydrated, and paraffin-embedded for histological assays. Three 
micrometer-thick tissue sections were used for hematoxylin-eosin histological staining. Blood 
was also collected for biochemical analyses.  Animals were maintained under controlled 
conditions of temperature (23 ± 5 °C), humidity (35 ± 5 %), and 12 h light/dark cycles. All 
animal experiments were conducted at the animal house located at the Faculty of Medicine, 
University of Porto, and were carried out by trained technicians in accordance with the 
European Community policy for Experimental Animal Studies [European Community law dated 
from November 24th 1986 (86/609/CEE) with addendum from June 18th 2007 (2007/526/CE)]. 
 
3.2.2. Oral glucose tolerance test and intraperitoneal insulin tolerance test  
All animals were fasted overnight after 19 weeks of treatment. To perform the oral glucose 
tolerance test (OGTT), all mice received a glucose solution of 1 g/Kg body weight by oral 
gavage. To analyze intraperitoneal insulin tolerance test (IPITT), animals were injected 
intraperitoneal with 0.75 U/Kg body weight of insulin (Sigma, Portugal). Blood glucose 
concentrations were measured 30 min before, at baseline and thereafter at 15, 30, 60, 90 and 
120 min after the glucose or insulin administration, with Precision Xtra Plus test strips and an 
Optium Xceed device (Abbott Diabetes Care, Ltd., Maidenhead, UK), according to the 
manufacturer’s instructions. Results are expressed as meanSD of the total area under the 
curve (AUC) calculated for each measurement. 
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3.2.3. Systemic biochemical measurements  
Plasma biochemical markers were assessed at the Department of Clinical Pathology, São 
João Hospital Center, using Olympus AU5400® automated clinical chemistry analyzer 
(Beckman-Coulter®, Izasa, Porto, Portugal). Hepatic function markers were determined through 
such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP) levels and metabolic status was evaluated through glucose, uric acid, TG, 
total cholesterol, VLDL, LDL, calculated according to Friedewald’s equation) and HDL levels. 
Plasma insulin levels were measured using a rat/mouse insulin ELISA kit (EZRMI-13K; Merck 
Milipore, Madrid, Spain). 
 
3.2.4. Insulin sensitivity and resistance indexes  
Insulin sensitivity and resistance indexes were calculated as follows : quantitative insulin 
sensitivity check index (QUICKI)=1/[log(I0) log(G0)], where I0 is fasting insulin (U/ml) and G0 is 
fasting glucose levels (mg/dL); and homeostasis model assessment (HOMA)=(G0 I0)/22.5, 
where  glucose was expressed as mg/dL and insulin was expressed as U/mL) (Lee et al., 
2008). 
 
3.2.5. Extraction and quantification of liver triglycerides and cholesterol levels 
TG and cholesterol were extracted from frozen liver samples, and were determined by 
colorimetric quantification kits for TG (ab65336; Abcam, UK) and cholesterol (ab65359; Abcam, 
UK), according to the manufacturer's instructions.  
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3.2.6. Tissue VEGF-B quantification by ELISA 
Liver and skeletal muscle VEGF-B concentration was quantified using Quantikine mouse 
VEGF-B (ABIN869657; Antibodies-online, USA) ELISA kit, using a microplate reader (Thermo 
Fisher Scientific, USA) in accordance with the manufacturer’s instructions.  
 
3.2.7. Western blot analyses for metabolic pathways 
Ten to twelve micrograms of total protein were separated by electrophoresis in a 10% SDS-
PAGE. Membranes were incubated with antibodies against AMPK (1:1000 dilution; ab80039 
Abcam, UK), phospho-AMPK (1:750 dilution; #2531 Cell signalling, UK), ACC (1:1000 dilution; 
#3662 Cell signalling, UK), phospho-ACC (1:750 dilution; #3661 Cell signalling, UK), SREBP-1c 
(1:1000 dilution; ab3259 Abcam, UK), CD36 (1:1000 dilution; sc-9154 Santa Cruz 
Biotechnology, Germany), FAS (1:1000 dilution; GTX50788 Genetex, CA, USA), VEGFR-1 (1:7500 
dilution; ab2350 Abcam, UK), phospho-AS160 (1:750 dilution; #8881 Cell signalling, UK), 
PFKFB3 (1:1000 dilution; #13123 Cell Signalling, UK) and β-actin (1:3000 dilution; ab8227 
Abcam, UK), followed by incubation with the respective secondary horseradish-peroxidase 
(HRP)-coupled antibody (1:10000; anti-rabbit sc-2040 and anti-mouse sc-2060 from Santa Cruz 
Biotechnology, Germany). The detection was performed using enhanced chemiluminescence 
(ECL kit; Biorad, USA). Mean relative intensities were quantified by densitometry (Vision Works 
LS software; UVP Inc., USA) and normalized to the signal intensity of β-actin or the signal 
intensity of total form for phosphorylated proteins. 
 
3.2.8. Statistical analyses 
Every assay was performed at least in three independent experiments. Statistical 
significance of different groups was evaluated by ANOVA followed by the Bonferroni post-hoc 
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test, with GraphPad prism version 7.0a software (GraphPad Software, Inc, CA, USA). A 
difference between experimental groups was considered significant with a confidence interval 
of 95 %, whenever p ≤ 0.05.  
 
3.3. Results 
3.3.1. XN and 8PN treatments affected body weight and plasma lipid profile 
As illustrated in Table 3.1, the mean body weight of DM animals (52.32.3 g) and DM-
Ethanol group (53.01.8 g) was significantly higher when compared to control mice group 
(32.71.9 g). Similarly, blood glucose levels increased 40 % in both DM and DM-Ethanol 
groups. However, both XN and 8PN treatments significantly suppressed the raise of body 
weight gain and glycemia, on 15 %.  
To characterize the general metabolic status of distinct animal groups, plasma levels of 
hepatic enzymes were quantified. As expected, both DM and DM-Ethanol groups presented 
higher AST, AST/ALT ratio, and ALP levels than control group (p < 0.001 for DM and p = 0.01 for 
DM-Ethanol). After XN and 8PN consumption, these parameters were attenuated in diabetic 
animals to levels identical to healthy controls. Plasma uric acid levels did not differ between 
experimental groups. Diabetic mice drinking water or ethanol exhibited increased levels of TG, 
cholesterol, LDL, VLDL and a reduced HDL (40 %) and HDL/LDL ratio (3-fold) levels when 
compared with control group. Remarkably, diabetic animals treated with XN and 8PN showed 
a lipid profile improvement with a statistical increase in HDL (101.36.4 g/L for DM-XN and 
99.65.6 g/L for DM-8PN vs 77.25.6 g/L for DM-Ethanol) and HDL/LDL ratio (3.80.9 for DM-
XN and 3.70.8 for DM-8PN vs 2.10.4 for DM-Ethanol) as well as a significant decrease on 
both TG (p = 0.04 for DM-XN and p = 0.001 for DM-8PN animals) and total cholesterol (p = 0.03 
for DM-XN and p=0.002 for DM-8PN) when compared to DM-Ethanol group. 
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Table 3.1 - Analysis of body weight and plasma biochemical markers in diabetic mice. Control, healthy mice; DM, 
diabetic animals fed with high-fat diet; DM-Ethanol, diabetic animals drinking 0.1% ethanol in water; DM-XN, diabetic 
animals treated with 10 mg/L XN; DM-8PN, diabetic animals consuming 10 mg/L 8PN. Evaluated parameters included 
body weight, hepatic function markers, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and 
alkaline phosphatase (ALP) activities and markers of metabolic status including glucose, insulin, uric acid, triglycerides, 
total cholesterol, very low density lipoprotein cholesterol (VLDL), low density lipoprotein cholesterol (LDL), and high 
density lipoprotein cholesterol (HDL). Results are expressed as means ± SD (5<n<6). *p < 0.05 vs control, # p < 0.05 vs 
DM; δ p < 0.05 vs DM-Ethanol. 
 Control DM DM-Ethanol DM-XN DM-8PN 
Body weight (g) 32.7±1.9 52.3±2.3* 53.0±1.9* 44.5±3.2*
♯δ
 46.7±4.6*
♯δ
 
Glucose (g/L) 154.67±8.77 211.16±8.08* 213.8±6.83* 183.5±11.47*
♯δ
 187.67±6.86*
♯δ
 
Insulin (U/mL) 0.24±0.03 0.61±0.06* 0.62±0.08* 0.43±0.07*
♯δ
 0.48±0.06*
♯δ
 
AST (U/L) 75.5±13.7 122.4±7.4* 124.3±9.54* 92.0±7.9
♯δ
 93.40±14.9
♯δ
 
ALT (U/L) 59.7±8.1 71.0±4.5 70.5±5.0 65.7±6.5 62.8±16.0 
AST/ALT 1.29±0.29 1.73±0.10* 1.77±0.13* 1.41±0.12 1.52±0.24 
ALP (U/L) 61.50±17.28 105.00±13.96* 94.00±15.51* 60.00±13.71
♯δ
 66.17±9.06
♯δ
 
Tryglicerides (g/L) 59.0±6.6 112.2±12.2* 108.8±20.6* 81.8±13.9
♯δ
 64.3±11.9
♯δ
 
Total cholesterol (g/L) 66.17±9.30 135.30±34.66* 127.60±15.53* 90.33±6.83
♯δ
 77.67±15.71
♯δ
 
VLDL (g/L) 10.18±2.86 17.40±3.21* 18.00±3.32* 13.27±1.84 13.33±2.82 
LDL (g/L) 22.67±3.83 37.83±5.04* 37.40±6.35* 27.67±5.47
♯
 28.33±6.09 
HDL (g/L) 119.33±8.52 67.83±3.24* 77.20±15.61* 101.33±6.44*
♯δ
 99.67±5.82*
♯δ
 
HDL/LDL 5.37±0.85 1.83±0.43* 2.09±0.45* 3.80±0.88*
♯δ
 3.66±0.81*
♯δ
 
Uric acid (mg/L) 1.42±0.26 2.47±0.93 2.53±0.22 1.88±0.57 1.68±0.46 
 
3.3.2. XN and 8PN treatments ameliorated glucose tolerance and insulin sensitivity  
To assess glycemic response and insulin sensitivity, an OGTT and an IPITT were performed. 
As depicted in Figure 3.1 A, DM and DM-Ethanol blood glucose levels following an oral glucose 
administration were significantly higher reaching the glycemic peak at 30 min, when compared 
with control group. In contrast, XN and 8PN consumption improved glucose tolerance as 
shown by the reduced glycemic peak and lower AUC measurement (Figure 3.1 B). Similar 
results were obtained with IPITT. DM and DM-Ethanol groups exhibited increased blood 
glucose levels that remained higher at all time-points up to 120 min (Figure 3.1 C), leading to 
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the highest AUC values, indicating insulin resistance when compared to control group (Figure 
3.1 D). XN and 8PN treatments ameliorated insulin sensitivity decreasing blood glucose levels 
to their own initial levels with significantly lower AUCs (p < 0.001 for DM-XN and p = 0.004 for 
DM-8PN). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accordingly, whereas diabetic animals from DM and DM-Ethanol groups presented around 
3.5-fold higher levels of insulin resistance and reduced insulin sensitivity as determined by 
HOMA (Figure 3.2 A) and QUICKI (Figure 3.2 B) respectively, XN and 8PN treatments reversed 
both indexes, when compared to DM-Ethanol group. 
Figure 3.1 - Effects of XN and 8PN treatments in glucose tolerance and insulin sensitivity in diabetic animals. Control, 
healthy mice; DM, diabetic animals fed with high-fat diet; DM-Ethanol, diabetic animals drinking 0.1 % ethanol in water; 
DM-XN, diabetic animals treated with 10 mg/L XN; DM-8PN, diabetic animals treated with 10 mg/L 8PN/L. (A) Oral 
glucose tolerance test (OGTT). All animals were fasted for 6 h, then 1 g/Kg glucose was given by oral gavage and blood 
glucose was monitored at 0, 15, 30, 60, 90 and 120 min. (B) Quantification of the area under the curve (AUC) from 
OGTT (C) Intraperitoneal insulin tolerance test (IPITT). The basal blood glucose level (0 min) was quantified before the 
intraperitoneal insulin injection (0.75 U/Kg). (D) Quantification of the area under the curve (AUC) from IPITT. Blood 
samples for glucose level determination were taken at 15, 30, 60, 90 and 120 min. Data are expressed as mean ± SD 
(5<n<6). *p < 0.05 vs control, # p < 0.05 vs DM; δ p < 0.05 vs DM-Ethanol. 
 
 Xanthohumol and 8-prenylnaringenin ameliorate diabetic-related metabolic dysfunctions in mice 
 
 
 42 
 
 
 
 
 
 
 
 
 
3.3.3. XN and 8PN treatment regulated the expression of AMPK-related metabolic 
enzymes 
To determine whether the effects of XN and 8PN on lipid profile could be mediated by 
AMPK activation, the expression of AMPK and target proteins was evaluated in mice liver and 
skeletal muscle. As shown in Figure 3.3 A-D and Figure 3.4 A-D, DM and DM-Ethanol animal 
groups significantly decreased in about 2-fold the activation of AMPK as revealed by 
phosphorylated/total ratio expression. This was accompanied by increased expression of 
SREBP-1c, FAS and a 2-fold decrease in phosphorylation (and subsequent inactivation) of ACC, 
when compared to control healthy animals in both liver and skeletal muscle. In contrast, this 
was prevented by XN and 8PN treatments leading to marked enhancement of the 
phosphorylation of AMPK in the liver (0.970.10 for DM-XN and 1.260.14 for DM-8PN vs 
0.570.12 DM-Ethanol) and in skeletal muscle (0.810.20 for DM-XN and 1.090.20 for DM-
8PN vs 0.460.11 DM-Ethanol). These findings were accompanied by reduced expression of 
SREBP-1c and FAS, and increased phosphorylated ACC in both tissues, implying a reduction in 
lipogenesis by these two compounds. 
 
Figure 3.2 - Glucose levels and insulin resistance in diabetic animals treated with XN and 8PN polyphenols. Control, 
healthy mice; DM, diabetic animals fed with high-fat diet; DM-Ethanol, diabetic animals drinking 0.1 % ethanol in water; 
DM-XN, diabetic animals treated with 10 mg/L XN; DM-8PN, diabetic animals treated with 10 mg/L 8PN. (A) HOMA at 
week 20 (B) QUICKI determination for insulin sensitivity assessment. Data are expressed as mean ± SD (5<n<6). *p < 
0.05 vs control, # p < 0.05 vs DM; δ p < 0.05 vs DM-Ethanol. 
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CD36 immunoblotting (Figure 3.3 E-F and Figure 3.4 E-F), responsible for the transport of 
LCFA to tissues, revealed that the hepatic and skeletal muscle protein expression was also 
significantly down-regulated in diabetic animals that ingested XN (30 % in liver and 30 % in 
skeletal muscle) and 8PN (30 % in liver and 20 % in skeletal muscle), in comparison with DM-
Ethanol. 
Figure 3.3 - Hepatic lipogenic enzymes and fatty acid transporter protein expression on diabetic animals treated with 
polyphenols. Control, healthy mice; DM, diabetic animals fed with high-fat diet; DM-Ethanol, diabetic animals drinking 
0.1 % ethanol in water; DM-XN, diabetic animals treated with 10 mg/L XN; DM-8PN, diabetic animals treated with 10 
mg/L 8PN. Expression of (A) pAMPK/AMPK ratio (B) SREBP-1c (C) pACC/ACC ratio (D) FAS (E) fatty acid transporter 
CD36, and (F) representative blots of immunoblotting obtained by western blotting analysis. Quantification of (G) 
triglycerides and (H) cholesterol content in hepatic tissue. Data are expressed as mean ± SD (5<n<6). *p < 0.05 vs 
control, # p < 0.05 vs DM; δ p < 0.05 vs DM-Ethanol. 
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TG and cholesterol levels were quantified in liver and skeletal muscle as indicators of lipid 
accumulation. Regarding TG levels (Figure 3.3 H and Figure 3.4 H), diabetic animals drinking 
water and ethanol displayed higher TG content comparing to control group (around 2-fold in 
liver and 1.5-fold in skeletal muscle). The levels of cholesterol were also higher in diabetic 
animals (2-fold in liver and 3-fold in skeletal muscle) comparing to control animals (Figure 3.3 I 
Figure 3.4 - Skeletal muscle lipogenic and -oxidation enzymes and fatty acid transporter protein expression on diabetic 
animals treated with polyphenols. Control, healthy mice; DM, diabetic animals fed with high-fat diet; DM-Ethanol, 
diabetic animals drinking 0.1 % ethanol in water; DM-XN, diabetic animals treated with 10 mg/L XN; DM-8PN, diabetic 
animals treated with 10 mg/L 8PN. Expression of (A) pAMPK/AMPK ratio (B) SREBP-1c (C) pACC/ACC ratio (D) FAS 
(E) fatty acid transporter CD36, (F) representative blots of immunoblotting obtained by western blotting analysis. 
Quantification of (G) triglycerides and (H) cholesterol content in skeletal muscle tissue. Data are expressed as mean ± 
SD (5<n<6). *p < 0.05 vs control, # p < 0.05 vs DM; δ p < 0.05 vs DM-Ethanol. 
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and Figure 3.4 I). However, a significant decrease of 30 % on cholesterol and TG content was 
observed in the liver of animals treated with XN and a 23 % reduction of liver TG in DM-8PN 
animals, comparing to DM-Ethanol group. An identical profile was observed in skeletal muscle. 
A significant decrease in TG levels was observed after XN (0.480.05 nmol/L) and 8PN 
(0.460.04 nmol/L) consumption, when compared to DM-Ethanol group (0.610.05 
nmol/L). Moreover, a tendency to reduced cholesterol levels after XN and 8PN treatments 
was also observed. 
 
3.3.4. Polyphenols modulated lipid uptake in diabetic mice 
Activation of VEGFR-1 by VEGF-B results in endothelial FA transport and uptake by 
peripheral tissues. Since this pathway is upregulated in diabetic tissues, we evaluated whether 
these polyphenols were able to prevent lipotoxicity. As depicted in Figure 3.5, DM and DM-
Ethanol groups exhibited 2-fold increased levels of VEGFR-1 in liver and 1.5-fold increase in 
skeletal muscle. VEGF-B levels were also approximately 2-fold higher in both tissues. However, 
the expression of VEGFR-1 and VEGF-B content were significantly reduced in the liver of 
diabetic animals treated with XN and 8PN by around 40 % (comparing to DM-Ethanol mice 
group).  
A significantly lower expression of both receptor and ligand was also found in skeletal 
muscle of diabetic mice upon XN or 8PN ingestion, being XN treatment more effective in 
decreasing VEGFR-1 than 8PN (0.780.10 for DM-XN and 1.010.08 for DM-8PN group). 
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3.3.5. XN and 8PN treatments affected glycolysis and glucose uptake  
As an effective activator of the glycolytic pathway, the expression of PFKFB3 and its 
modulation by polyphenol’s consumption is shown in Figure 3.6. An increase of 1.5-fold was 
observed in this glycolytic activator in DM and DM-Ethanol groups in both liver and skeletal 
muscle, compared to control animals. In contrast, XN consumption prevented this effect with a 
significant decrease in PFKFB3 expression in the liver (0.810.06) and in skeletal muscle 
(0.800.20) in comparison to DM-Ethanol group (1.120.09 and 1.130.19, respectively). 
Diabetic animals treated with 8PN exhibited a significant reduction in PFKFB3 expression only 
in skeletal muscle (0.970.15 vs 1.300.19 for DM-Ethanol).  
 
 
Figure 3.5 - The VEGFR-1 expression in (A) liver and (B) skeletal muscle on diabetic animals treated with polyphenols. 
Control, healthy mice; DM, diabetic animals fed with HFD; DM-Ethanol, diabetic animals drinking 0.1 % ethanol in water; 
DM-XN, diabetic animals treated with 10 mg/L XN; DM-8PN, diabetic animals treated with 10 mg/L 8PN. (C) 
Representative blots of immunoblotting obtained by Western blotting analysis are shown.  Determination of VEGF-B by 
ELISA assay in (D) liver and in (E) skeletal muscle. Data are expressed as mean ± SD (5<n<6). *p < 0.05 vs control, # p 
< 0.05 vs DM; δ p < 0.05 vs DM-Ethanol. 
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These findings led us to quantify AS160 in order to evaluate whether XN and 8PN 
treatment could ameliorate glucose uptake in skeletal muscle. As illustrated in figure 6 C-D, 
DM and DM-Ethanol groups downregulated phospho-AS160 expression (0.990.22 for DM and 
0.880.12 for DM-Ethanol) in comparison to control group (1.510.24). Normal levels of 
phospho-AS160 expression were restored upon XN (1.400.18) and 8PN consumption 
(1.310.09) (Figure 3.6 C and D), suggesting an increase in glucose uptake in diabetic muscle by 
these two compounds. 
 
Figure 3.6 - Glycolytic regulator PFKFB3 protein expression in (A) liver and in (B) skeletal muscle and (C) phospho-
AS160 protein expression in skeletal muscle, involved in the translocation of GLUT4 to the skeletal muscle plasma 
membrane, on diabetic animals treated with polyphenols. Control, healthy mice; DM, diabetic animals fed with high-fat 
diet; DM-Ethanol, diabetic animals drinking 0.1 % ethanol in water; DM-XN, diabetic animals treated with 10 mg/L XN; 
DM-8PN, diabetic animals treated with 10 mg/L 8PN. (D) Representative images of immunoblotting obtained by 
Western blotting analysis are shown. Results are expressed as means ± SD (5<n<6). *p < 0.05 vs control, # p < 0.05 vs 
DM; δ p < 0.05 vs DM-Ethanol. 
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3.4. Discussion 
T2DM is characterized by hyperglycemia, insulin resistance, dyslipidemia, oxidative stress, 
chronic inflammation and angiogenesis. Our previous work focused in XN and 8PN modulation 
of oxidative stress, inflammation and angiogenesis, three intermingled processes implicated in 
DM (Negrão et al., 2010; Costa et al., 2013). In the present study, C57Bl/6 mice fed with HFD 
were used to address the effects of XN and 8PN treatments in diabetic-related metabolic 
complications. Corroborating recent evidence regarding XN effects in metabolism (Miyata et 
al., 2015), the present work further highlights novel targets for therapeutic interventions, and 
reports for the first time the metabolic effects of 8PN. 
Besides lowering body weight gain and fasting hyperglycemia in diabetic mice, these 
findings showed that XN and 8PN also ameliorated plasma lipid profile, reducing total 
cholesterol and TG levels, comparatively to DM-Ethanol animal group. Moreover, OGTT and 
IPITT assays revealed that both polyphenols counteract HFD-induced glucose intolerance and 
insulin resistance in diabetic mice, which are corroborated with HOMA and QUICKI 
determinations of insulin resistance and sensitivity, respectively. In agreement with this, other 
authors reported that polyphenols consumption improves cardiovascular health, blood 
pressure, LDL levels and insulin resistance (Yui et al., 2014; Grassi et al., 2015).  
Concomitantly, XN and 8PN consumption modulated metabolic-related protein expression 
in diabetic mice hepatic and skeletal muscle. In line with the effects observed by other 
polyphenols, the current study demonstrated that both XN and 8PN activated AMPK, a key 
energy sensor involved in the regulation of energy metabolic pathways (Sears et al., 2012; Guo 
et al., 2015). Once activated, AMPK inhibits SREBP-1c expression, as well as its downstream 
lipogenesis enzyme targets, ACC and FAS. These findings are in accordance with the systemic 
lipid profile improvement, body weight gain, enhancement in insulin sensitivity and glucose 
tolerance observed.  
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In order to generate energy, liver and skeletal muscle oxidize LCFA transported from the 
blood into tissues mainly through CD36, which has been shown to be augmented in T2DM, 
leading to increased uptake of FFA (Miquilena-Colina et al., 2011). In fact, increased hepatic 
and muscle CD36 expression plays a causative role in the pathogenesis of T2DM contributing 
to the diabetes-associated dyslipidemia (Koonen et al., 2007; Goldberg et al., 2009). The 
expression of CD36 transporter was downregulated in animals treated with polyphenols, which 
probably results in decreasing FA uptake by the tissues as documented by other authors (Aoun 
et al., 2011).  
In addition, increased hepatic and skeletal muscle VEGFR-1 and its ligand VEFG-B 
expression was found in our diabetic animals. VEGF-B binds to its receptor, inducing the 
expression of FATP that are involved in the lipid transport and uptake from EC to tissues 
(Hagberg et al., 2010). XN or 8PN treatment caused a reduction in both VEGFR-1 and VEGF-B in 
diabetic mice, suggesting that the intake of these two polyphenols prevents ectopic lipid 
accumulation. Hagberg and colleagues reported that VEGF-B did not affect CD36 expression 
(Hagberg et al., 2010), however according to our results both VEGFR-1 and CD36 were 
increased in diabetic animals and down-regulated by XN and 8PN treatment. These findings 
suggest that both pathways were independently up-regulated in T2DM, contributing to an 
increase in TG and cholesterol content in hepatic and skeletal muscle of diabetic animals 
observed in the current study. Moreover, the XN and 8PN consumption diminished the 
expression of VEGFR-1/VEGF-B and also CD36 transporter, concomitant with a decreased in TG 
and cholesterol content within the tissues.  
These findings led to the assumption that this signaling pathway is of great interest as a 
target in metabolic disorders, since it is related with improved glucose tolerance, further 
restoring insulin sensitivity in T2DM (Hagberg et al., 2010; Hagberg et al., 2012; Carmeliet et 
al., 2012).  
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In T2DM, hepatic glucose production is increased as a consequence of an impaired insulin 
capacity to stimulate glucose uptake by peripheral organs as skeletal muscle (Cryer, 2012). The 
antidiabetic effect of XN and 8PN was additionally demonstrated through reduced hepatic and 
skeletal muscle PFKFB3 expression, an important glycolytic regulator, known as a modulator of 
insulin action (Trefely et al., 2015). Modulation of PFKFB3 activity or glycolysis pathway affects 
insulin signaling. Thereafter, insulin activates PI3K/AKT signaling pathway, which 
phosphorylates AS160 downstream substrate, triggering GLUT-4 translocation to cell 
membrane (Klip, 2009). In the present study, PFKFB3 was identified as a positive regulatory 
kinase of GLUT-4 translocation as its downregulation by polyphenol’s consumption leads to the 
impairment on AS160 expression. Accordingly, animals fed with HFD displayed an impairment 
in GLUT-4 translocation to plasma membrane. Our data suggests that XN and 8PN ingestion 
increased phospho-AS160 expression, which is known to lead to GLUT-4 membrane 
translocation, improving skeletal muscle glucose uptake. These findings are further 
corroborated by the reduction in glycemia and increase in insulin sensitivity upon these 
compounds intake. 
Altogether, the present work provides evidence that both XN and 8PN treatments protect 
mice against the development of T2DM metabolic-related complications.  The XN and 8PN 
consumption exerted their beneficial effects by reducing body weight gain, preventing insulin 
resistance and modulating lipid and glucose metabolic pathways. They exert beneficial effects 
by a metabolic switch from FA synthesis to oxidation and promoting muscle glucose uptake. 
Our findings suggest a potential dietary strategy for preventing common metabolic diseases as 
T2DM. 
XN and 8PN are natural multifunctional compounds that confer multiple health benefits by 
acting simultaneously in multiple targets. Despite not enough data is available regarding the 
metabolic effects of 8PN in diabetes, our data highlight the promising benefits of this 
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compound in the protection against T2DM-related metabolic dysfunctions. Nevertheless, 
additional experimental studies are required to better understand the underlying mechanisms 
of potential effects of these two polyphenols. 
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4. Modulation of VEGF signaling in a mouse model of diabetes 
by xanthohumol and 8-prenylnaringenin: Unveiling the 
angiogenic paradox and metabolism interplay 
 
4.1. Background 
The prevalence of obesity and associated T2DM has increased dramatically in the last 
decades. T2DM is a chronic, multifactorial and progressive disease, which affects more than 
300 million people worldwide, being considered a major public health threat. Diabetes is 
characterized by hyperglycemia due to a deficiency in insulin production and/or its resistance, 
which contributes to endothelial dysfunction, resulting in macro and microvascular 
complications (Brownlee, 2001; Blake et al., 2014). Diabetic patients have a high incidence of 
renal disease, lower limb amputation, and retinopathy that are important causes of morbidity, 
and portend an increased risk to develop cardiovascular disease responsible for a significant 
number of deaths (Schnuelle et al., 2011). 
T2DM is a paradoxical disease regarding vascular complications. Increased 
neovascularization in organs such as the kidney and retina, coexist with a marked inhibition of 
new vessel growth in coronary heart disease and peripheral arterial disease (Soares et al., 
2009). Although the angiogenic paradox is well established in diabetes, the molecular 
mechanisms underlying these distinct vascular phenotypes in different organs remain unclear. 
Angiogenic EC relies on glycolysis for rapidly generating energy to migrate and proliferate 
to avascular areas. Recently, it has been reported that PFKFB3, a bifunctional enzyme 
abundant in EC, plays an important role in ensuring the high glycolytic flux that promotes 
vessel growth (De Bock et al., 2013; Eichmann et al., 2013; Zecchin et al., 2015). In fact, its 
kinase activity is more active than the phosphatase, favoring F-2,6-BP synthesis, a potent 
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allosteric activator of 6- PFK-1 key glycolytic enzyme (Van Schaftingen et al., 1982). When 
PFKFB3 is silenced in vitro or inactivated in vivo, glycolysis becomes partially and transiently 
suppressed and angiogenesis impaired inducing EC quiescence (Schoors, De Bock, et al., 2014).  
The cross talk between angiogenesis and endothelial metabolism also enrolls VEGF 
signaling pathway. VEGF-A stimulates endothelial response through VEGFR-2 tyrosine kinase 
activity (Ferrara et al., 2005; Roskoski, 2007; Waltenberger, 2009; Koch et al., 2012), and also 
has affinity to bind to VEGFR-1 but with poor signal transduction (Rahimi, 2006; Robinson et 
al., 2001). Conversely, VEGFR-1 and NP-1 co-receptor bind to VEGF-B (Li, 2010; Bry et al., 
2010), which has recently been associated to endothelial lipid metabolism. VEGF-B induces the 
expression of FATP mediating the transport and the uptake of dietary lipids to peripheral 
tissues through EC (Hagberg et al., 2010; Li, 2010). Blocking VEGF-B signaling has attracted 
considerable attention in metabolic diseases, as it may prevent ectopic lipid accumulation and 
restore insulin sensitivity in obesity and T2DM animal models (Carmeliet et al., 2012; Hagberg 
et al., 2013; Muhl et al., 2016).  
Several approaches are used in T2DM management, namely insulin and oral anti-diabetic 
drugs or a combination therapy of both. However, they often exhibit undesirable side effects 
and fail to alter the course of long-term complications in many organs and to achieve and 
maintain long-term glycemic control. The development of alternative therapeutic approaches 
may include natural bioactive compounds as polyphenols that are present in fruits, vegetables 
and some beverages, including beer, green tea and wine. Moreover, evidence from animal and 
clinical studies suggests that the consumption of polyphenol-rich diets provide a variety of 
health benefits, including antioxidant, anti-inflammatory, antiatherogenic, among others 
(Vinson et al., 2003; Imhof et al., 2004). In recent years, much attention focused on the 
promising therapeutic potential of polyphenols in metabolic diseases, namely metabolic 
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syndrome, a cluster of risk factors that predispose to cardiovascular disease, cancer and T2DM 
(Rosell et al., 2003; Nozawa, 2005; Gerhauser, 2005a; Legette et al., 2012; Scoditti et al., 2012). 
Beer-derived XN, the main hop flavonoid, has substantial health-promoting properties and 
is mainly converted into IXN and then into 8PN phytoestrogen during beer production and 
after in vivo metabolism by liver microsomes and intestinal bacteria (Nikolic et al., 2006; 
Possemiers et al., 2008; Possemiers et al., 2009). We previously demonstrated that whereas 
topic administration of 8PN stimulates the growth of neovessels, XN and IXN exhibit anti-
angiogenic and anti-inflammatory properties in a wound healing in vivo assay (Negrão et al., 
2010). Recently, it was reported that XN exerts anti-obesity activity and affect lipid and glycolic 
metabolism in rats with diet-induced T2DM (Bobak et al., 2003; Nozawa, 2005; Gorinstein et 
al., 2007; Legette et al., 2012; Kiyofuji et al., 2014; Legette et al., 2014; Sumiyoshi et al., 2013; 
Yui et al., 2014; Miranda et al., 2016a). Dietary phytoestrogens consumption also ameliorates 
insulin sensitivity, energy homeostasis and metabolic complications on animals and in post-
menopausal women (Cederroth et al., 2009; Llaneza et al., 2010; Andreoli et al., 2015).  
Thus nutritional polyphenols supplementation both acting in the endothelium, and 
improving metabolic dysfunction are putative tissue specific-target agents, potentially allowing 
a better resolution of T2DM-related complications. The current study aimed to examine the 
effect of XN and 8PN in diabetic vascular complications. 
 
4.2. Material and methods 
4.2.1. Animals and experimental mice treatment  
Thirty C57Bl/6 6-week old male mice (Charles-River, Spain) were randomly divided into 5 
experimental groups (n=6), and fed with different diets and beverages during 20 weeks: 
Standard diet (Control, C); High-fat diet (DM); HFD and 0.1 % ethanol in drink water (DM-
Ethanol); HFD and 10 mg/L XN (Hopsteiner, Germany) in 0.1 % ethanol (DM-XN); HFD and 10 
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mg/L 8PN in 0.1 % ethanol (DM-8PN). 8PN was synthetized according to previously described 
procedures (Zierau et al., 2002). Briefly, starting from acetylation of commercially available 
naringenin, the 7,4’-diacethyl-naringenin derivative was O-prenylated by the Mitsunobu 
reaction and following the tandem Claisen-Cope rearrangement of 5-prenyl-7,4-
diacetylnaringenin with Eu(fod)3, 8PN was obtained in 32 % yield. XN and 8PN were 
administered in a dose of 10 mg/L previously studied by our group, equivalent to 1 mg/Kg/day, 
which is in line with the doses reported previously without displaying hepatotoxic effects 
(Negrão et al., 2012; Costa et al., 2013). Polyphenols consumption was administered 
throughout the 20 weeks of experiment, the duration necessary to establish hyperglycemic 
conditions. A control of diabetic animals with 0.1 % ethanol in water (DM-Ethanol) was 
included, corresponding to the final ethanol concentration in polyphenols treatment. 
HFD was obtained from Research diets, USA. This mouse strain is prone to develop T2DM 
under HFD ingestion, displaying significant dyslipidemia, insulin resistance, and glucose 
intolerance (Cong et al., 2008).  
During the treatment period, body weight, glycemia, food and beverage intake were 
monitored. Glycemic control was monitored by measuring blood glucose obtained by pricking 
the vein from the tip of the tail using a sterile needle once a week with Precision Xtra Plus test 
strips and an Optium Xceed device (Abbott Diabetes Care, Ltd., Maidenhead, UK), according to 
the manufacturer’s instructions. Plasma insulin levels were measured using a rat/mouse insulin 
ELISA kit (EZRMI-13K; Merck Milipore, Madrid, Spain). 
Beverages were renewed every two days and were kept in dark bottles to avoid 
degradation. After 20 weeks of treatment, animals were sacrificed and left ventricle and 
kidney were frozen at -80 ºC for molecular analyses or fixed in 10 % neutral-buffered formalin, 
dehydrated, and paraffin-embedded for histological assays. Three micrometer-thick tissue 
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sections were used for histological and immunohistochemistry analysis. Blood was also 
collected for biochemical analyses.  
Animals were maintained under controlled conditions of temperature (23 ± 5 °C), humidity 
(35 ± 5 %), and 12 h light/dark cycles and access to diet and beverages were allowed ad 
libitum. All animal experiments were conducted at the animal house located at the Faculty of 
Medicine, University of Porto, and were carried out by trained technicians in accordance with 
the European Community policy for Experimental Animal Studies [European Community law 
dated from November 24th 1986 (86/609/CEE) with addendum from June 18th 2007 
(2007/526/CE)]. The project was approved by the Portuguese National Authority for Animal 
Health, DGAV, Portugal. 
 
4.2.2. Microvessel Density Evaluation  
Immunohistochemistry was performed in kidney and left ventricle paraffin sections with 
anti-CD31 antibody (1:100 dilution; ab 28364; Abcam, UK), as previously described (Negrão et 
al., 2012). 
The number of vessels was counted in three tissue sections for each animal and normalized 
to the total tissue area. A negative control was included. Any positive-stained EC or cluster that 
was separated from adjacent vessels was considered an individual vessel.  
 
4.2.3. VEGF-A, VEGF-B and phosphorylated VEGFR-2 quantification by ELISA  
Plasma and tissue VEGF-A and VEGF-B concentrations were quantified using Quantikine 
mouse VEGF-A (R&D Systems, UK) and mouse VEGF-B (ABIN869657, Antibodies-online, USA) 
ELISA kit. Levels of phosphorylated VEGFR-2 in cell lysates were measured using a Duoset 
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human Phospho-VEGFR-2 (Tyr 1175) ELISA kit (R&D Systems, UK), using a microplate reader 
(Thermo Fisher Scientific, USA) in accordance with the manufacturer’s instructions. 
 
4.2.4. Western blot analyses for angiogenic pathways 
Ten to twelve micrograms of total protein were separated by electrophoresis in a 10 % 
SDS-PAGE. After transfer to a nitrocellulose membrane (Biorad, USA), membranes were 
incubated overnight with antibodies against VEGFR-2 (1:750 dilution; #2479 Cell signalling, 
UK), phospho-VEGFR-2 (1:750 dilution; #2478 Cell signalling, UK), AKT (1:1000 dilution; #9272 
Cell signalling, UK), phospho-AKT (1:750 dilution; #4051 Cell signalling, UK), ERK (1:1000 
dilution; #9102 Cell signalling, UK), phospho-ERK (1:750 dilution; #4370 Cell signalling, UK), 
VEGFR-1 (1:7500 dilution; ab2350 Abcam, UK), NP-1 (1:1000 dilution; ab25998 Abcam, UK), 
PFKFB3 (1:1000 dilution; #13123 Abcam, UK) and β-actin (1:3000 dilution; ab8227 Abcam, UK), 
followed by incubation with the respective secondary horseradish-peroxidase (HRP)-coupled 
antibody (1:10000; anti-rabbit sc-2040 and anti-mouse sc-2060 from Santa Cruz Biotechnology, 
Germany), during 2 hours. The detection was performed using enhanced chemiluminescence 
(ECL kit; Biorad, USA). Mean relative intensities of the different proteins expression were 
quantified by densitometry (Vision Works LS software; UVP Inc., USA) and normalized with the 
signal intensity of β-actin or the signal intensity of total form for phosphorylated proteins. 
 
4.2.5. Cell culture and polyphenol treatment of HMECs 
Human microvascular endothelial cells (HMEC-1; ATCC, UK) were cultured in RPMI 1640 
medium supplemented with 10 % fetal bovine serum (FBS; Invitrogen Life Technologies, UK), 1 
% penicillin/streptomycin (Invitrogen Life Technologies, UK), 1.176 g/L sodium bicarbonate, 
4.76 g/L HEPES, 10 μg/mL EGF and 1 mg/L hydrocortisone >98 % (Sigma, Portugal), and were 
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maintained at 37ºC in a humidified 5 % CO2 atmosphere. All experiments were performed 
between passages 4 and 9. Treatments were performed for 5 min and 24 h in serum-free 
conditions and with 5.5 mM or 20 mM glucose concentration, to mimic diabetic condition. To 
evaluate whether polyphenols interact directly with VEGF-A, a pre-incubation of VEGF-A (25 
ng/mL; Sigma, Portugal) with polyphenols (XN and 8PN at 1 μM) was performed during 5 min, 
and then HMECs were washed twice and incubated with the mixed VEGF-A/polyphenol 
solution during 5 min or 24 h. At the same time-points, HMECs were incubated with 
polyphenols alone followed by stimulation with 50 ng/mL VEGF-A for 5 min. Control assays 
included vehicle control (0.1 % ethanol); a positive control (25 ng/mL VEGF-A) and a VEGFR-2 
inhibitor was used as a negative control (1 nM cabozantinib, Santa Cruz Biotechnology, 
Germany). Cells were lysed with RIPA buffer containing protease and phosphatase inhibitors 
and proteins were extracted and used in phosphorylated-VEGFR-2 ELISA assay as previously 
described. The results are expressed as percentage change relative to ethanol 0.1 %. 
 
4.2.6. Statistical analysis 
Every assay was performed at least in three independent experiments. Statistical 
significance of different groups was evaluated by ANOVA followed by the Bonferroni post-hoc 
test. In order to compare body weight and glycemia differences during 20 weeks, were 
evaluated by repeated measures two-way ANOVA, followed by the Bonferroni post-hoc test. 
The normality of data distribution was assessed Shapiro-Wilk test and for the homogeneity of 
variance the Levene’s test was used. A difference between experimental groups was 
considered significant with a confidence interval of 95 %, whenever p ≤ 0.05.  
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4.3. Results  
4.3.1. Polyphenols reduced body weight gain and glycemia in diabetic mice 
At the onset of the studies, the five mice groups revealed similar mean body weight 
gain (A) and blood glucose levels (B) as illustrated in Figure 4.1. During the 20-week 
experiment, body weight gain and blood glucose levels of diabetic animals were 
significantly higher as compared to control group. 
No significant difference was observed between DM and DM-Ethanol groups. Interestingly, 
XN and 8PN treatment significantly suppressed weight gain and glycemia relatively to diabetic 
ethanol group. To assess if the beverage consumption affects food intake, we monitor both 
parameters during the 20 weeks. Every experimental group drank the same volume of 
Figure 4.1 - Mean values for body weight (A), blood glucose levels (B), beverage consumption (C) and food intake (D) 
monitored weekly in mice with distinct treatments during 20 weeks. Quantification of insulin plasmatic levels at 20 weeks 
(E). Control, healthy (standard diet-fed) mice; DM, diabetic animals (fed with HFD); DM-Ethanol, diabetic animals 
drinking 0.1 % ethanol; DM-XN, diabetic animals treated with 10 mg/L XN; DM-8PN, diabetic animals consuming 10 
mg/L 8PN. Results are expressed as means ± SD (5<n<6). *p ≤ 0.05 vs control; # p ≤ 0.05 vs DM; δ p ≤ 0.05 vs DM-
Ethanol at week 20. 
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beverage (Figure 4.1 C) and consumed the same amount of food (Figure 4.1 D) per body 
weight. 
Insulin plasmatic measurements were also performed at the end of the study to confirm 
the diabetic condition in our animal model. In accordance to the raised hyperglycemia in DM 
(0.610.03 U/mL) and DM-Ethanol group (0.620.08 U/mL), insulin plasmatic levels were 
also higher in DM and DM-Ethanol group when compared to control (0.240.03 U/mL) as 
depicted in Figure 4.1E. DM-XN (0.430.07 U/mL) and DM-8PN (0.490.06 U/mL) were able 
to counteract these effect leading to decreased plasmatic glucose and insulin levels as those 
presented by DM-Ethanol group.  
 
4.3.2. Dietary XN and 8PN affected kidney and left ventricle neovascularization in DM 
animals 
The development of T2DM comprises distinct extracellular matrix remodeling and 
deregulated angiogenesis in different organs. We next evaluated whether XN and 8PN 
interfere with the number of vessels in diabetic mice kidney and left ventricle.  
A significant increase in the number of CD31 endothelial-stained vessels was found in 
kidneys of diabetic animals drinking water (127.0±21.8 vessels/mm2) and 0.1 % ethanol 
(123.7±23.4 vessels/mm2) compared to control animals fed with normal diet (68.2±12.5 
vessels/mm2) (Figure 4.2 A and C). Upon polyphenol treatment, the number of vessels 
decreased to control values, being statistically significant for XN-treated animals (70.7±21.5 
vessels/mm2). Consumption of 8PN did not show significant differences (92.9±10.1 
vessels/mm2), when compared to DM-Ethanol group (δ p≤0.05 vs DM-Ethanol). 
Inversely, in the left ventricle (Figure 4.2 B and C), angiogenesis was impaired with a 
significant reduction in the number of vessels in DM (154.1±40.2 vessels/mm2) and DM-
Ethanol group (204.0±30.3 vessels/mm2) when compared to healthy control (297.4±35.1 
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vessels/mm2). In contrast, XN (244.0±25.2 vessels/mm2) and 8PN (353.7±60.9 vessels/mm2) 
administration increased microvessel density in comparison to diabetic animals that did not 
consume polyphenols. Treatment with 8PN reached statistical significance when compared 
with DM-Ethanol group (Figure 4.2 B and C). 
 
 
4.3.3. XN and 8PN affected systemic and local VEGF-A and VEGF-B levels of DM mice 
Polyphenols effect on VEGF-A and VEGF-B concentrations in plasma and kidney and left 
ventricle tissue lysates were addressed by ELISA assay. As illustrated in Figure 4.3 A, diabetic 
animals consuming water (82.3±12.7 pg/mL) or 0.1 % ethanol (89.8±10.2 pg/mL) displayed 
reduced systemic levels of VEGF-A when compared to healthy control group (120.9±16.0 
Figure 4.2 - Quantification of blood vessels in kidney (A) and left ventricle (B) in healthy and diabetic animals upon 
distinct treatments during 20 weeks. (C) Representative images of immunohistochemistry with CD31 staining in kidney 
and left ventricle. Control, healthy (standard diet-fed) mice; DM, diabetic animals (fed with HFD); DM-Ethanol, diabetic 
animals drinking 0.1 % ethanol; DM-XN, diabetic animals treated with 10 mg/L XN; DM-8PN, diabetic animals 
consuming 10 mg/L 8PN. Results are expressed as means ± SD (5<n<6). *p ≤ 0.05 vs control; # p ≤ 0.05 vs DM; δ p ≤ 
0.05 vs DM-Ethanol. 
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pg/mL). XN did not change this effect (87.6±15.8 pg/mL). Nevertheless, the 8PN group 
exhibited a significant elevation of plasma VEGF-A levels to control values (142.2±25.9 pg/mL). 
 
Quantitative analysis of VEGF-A in kidney and left ventricle followed the vascular profile 
previously observed (Figure 4.2). In kidney (Figure 4.3 B) VEGF-A levels augmented in DM mice 
(508.9±39.8 pg/mL) and in DM-Ethanol animals (439.9±27.3 pg/mL) when compared to healthy 
controls (254.9±62.7 pg/mL). This increase was prevented in animals that consumed 
polyphenols, reaching statistical significance after XN intake (261.2±36.7 pg/mL). An opposite 
behavior was seen in left ventricle with a significant decrease in VEGF-A in all diabetic animal 
groups, except for 8PN-treated animals, which led to VEGF-A stimulation (244.4±20.2 pg/mL) 
to healthy control levels (242.6±45.1 pg/mL).  
Given the recently reported role of VEGF-B in endothelial metabolism (Hagberg et al., 
2010; Hagberg et al., 2013), VEGF-B was also quantified in these animals. Plasma and tissue 
Figure 4.3 - Quantification of systemic and tissue levels of VEGF-A (A and B) and VEGF-B (C and D) in healthy and 
T2DM animals subjected to distinct treatments during 20 weeks. Control, healthy (standard diet-fed) mice; DM, diabetic 
animals (fed with HFD); DM-Ethanol, diabetic animals drinking 0.1 % ethanol; DM-XN, diabetic animals treated with 10 
mg/L XN; DM-8PN, diabetic animals consuming 10 mg/L 8PN. Results are expressed as means ± SD (5<n<6). *p ≤ 0.05 
vs control; # p ≤ 0.05 vs DM; δ p ≤ 0.05 vs DM-Ethanol, γ p ≤ 0.05 vs DM-XN. 
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VEGF-B levels (Figure 4.3  C and D) revealed an identical pattern, increasing in diabetic animals 
subjected to treatment with water (77.9±4.6 pg/mL in plasma; 556.5±37.4 pg/mL in kidney; 
826.9±28.5 pg/mL in left ventricle) and 0.1 % ethanol (75.5±4.5 pg/mL in plasma; 605.6±18.8 
pg/mL in kidney; 697.3±58.1 pg/mL in left ventricle) when compared to non-diabetic controls 
(43.0±8.4 pg/mL in plasma; 382.7±11.3 pg/mL in kidney; 604.0±68.7 pg/mL in left ventricle). 
Inversely, a significant reduction to control values was observed upon XN (54.1±8.5 pg/mL in 
plasma; 398.1±35.0 pg/mL in kidney; 572.7±53.5 pg/mL in left ventricle) and 8PN (61.4±5.78 
pg/mL in plasma; 434.8±74.5 pg/mL in kidney; 656.5±70.1 pg/mL in left ventricle) 
consumption. 
 
4.3.4. Polyphenols modulated VEGF angiogenic pathway in diabetic mice 
Since the angiogenesis are important targets in metabolic disorders, namely cancer and 
T2DM, the potential preventive activity of dietary polyphenols in the VEGF signaling pathway 
in diabetic mice was investigated. VEGFR-2 is expressed in EC and is the predominant receptor 
involved in angiogenic signaling. Increase of VEGFR-2 activation (2.03±0.5 in DM and 1.83±0.1 
in DM-Ethanol) and its downstream effectors, pERK/ERK (2.17±0.2 in DM and 2.11±0.4 in DM-
Ethanol) and pAKT/AKT (1.19±0.2 in DM and 1.03±0.1 in DM-Ethanol), was observed in kidney 
lysates (DM and DM-Ethanol) when compared to control (Figure 4.4 A, B, C and G). After XN 
consumption, VEGFR-2 activation in the kidney was prevented (0.64±0.2) as well as its 
downstream effectors pERK (1.42±0.3) and pAKT (0.70±0.06), when compared to DM-Ethanol. 
Strikingly, reduction of this pathway by 8PN treatment only reaches significant relevance for 
pERK/ERK (1.32±0.24) protein expression.  
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Conversely, in left ventricle, a significant reduction on phospho-VEGFR-2 and related ERK 
and AKT activation in DM mice (0.47±0.1; 0.98±0.2; 0.95±0.1, respectively) and DM drinking 
0.1 % ethanol (0.35±0.1; 0.95±0.2; 0.91±0.1, respectively) was found when compared to 
healthy control group (1.01±0.1; 1.73±0.2; 1.77±0.2, respectively) (Figure 4.4 D, E, F, and H). 
Upon 8PN treatment, the expression of VEGFR-2 (1.20±0.2) and downstream pERK/ERK 
(1.63±0.1) and pAKT/AKT (1.58±0.2) effectors were significantly activated. Surprisingly, XN was 
also able to activate VEGFR-2 (0.75±0.1) and AKT (1.43±0.1) in left ventricle when compared to 
DM-Ethanol group, although, without reaching healthy control levels.  
Figure 4.4 - Expression of VEGFR-2 and downstream molecules ERK and AKT in kidney (A-C) and in left ventricle (D-
F) by Western blot analyses, in healthy and T2DM animals subjected to distinct treatments during 20 weeks. A 
representative Western blotting is shown (G and H). Control, healthy (standard diet-fed) mice; DM, diabetic animals (fed 
with HFD); DM-Ethanol, diabetic animals drinking 0.1 % ethanol; DM-XN, diabetic animals treated with 10 mg/L XN; 
DM-8PN, diabetic animals consuming 10 mg/L 8PN. Results are expressed as means ± SD (5<n<6). *p ≤ 0.05 vs 
control; # p ≤ 0.05 vs DM; δ p ≤ 0.05 vs DM-Ethanol, γ p ≤ 0.05 vs DM-XN. 
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To better understand the dual effect of XN and 8PN in modulating VEGFR-2 
phosphorylation, a cell culture assay was performed in the presence or absence of VEGF-A. 
Incubation of HMEC with XN either for 5 min or 24 h, led to a significant decrease in VEGFR-2 
activity (Figure 4.5, assay 1). This effect was even enhanced when XN-treated HMECs were 
stimulated with VEGF-A for 5 min (Figure 4.5, assay 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 - XN and 8PN modulate VEGFR-2 activation in endothelial cells by ELISA assay. (A) HMEC were exposed to 
normal (5.5 mM glucose) and hyperglycemia (20 mM glucose) conditions. HMEC were incubated with 1 μM XN or 8PN 
for 5 min and 24 h (1). HMEC were incubated with 1 μM XN or 8PN for 5 min and 24 h and then stimulated with VEGF-A 
for 5 min (2). HMEC were co-incubated with XN or 8PN and VEGF for 5 min and 24 h (3). (B) Schematic representation 
of cell culture experimental design. Results are expressed as percentage of ethanol control at each time point and 
glucose concentration and presented as mean ± SD (n=4) *p ≤ 0.05 versus control; δ p ≤ 0.05 versus normal glucose. 
C-, HMECs treated with VEGFR-2 Inhibitor; C+, HMECs incubated with VEGF for 24h. 
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As depicted in Figure 4.5 (assay 3) prior co-incubation of XN with 50 ng/mL VEGF-A for 5 
min, resulted in an 87 % reduction of VEGFR-2 activation to levels similar to those achieved 
with VEGFR-2 inhibitor, implying that anti-angiogenic effects of XN may be due to VEGF-A 
quenching by this polyphenol. 
Conversely, HMEC incubated with 8PN exhibited a significant activation of VEGFR-2 only in 
the absence of VEGF-A (Figure 4.5, assay 1). When HMEC were previously incubated with 8PN 
and then stimulated with VEGF-A or co-incubated with a mixture of 8PN and VEGF-A, no 
significant effect on VEGFR-2 activation was detected.  These findings indicate that 8PN pro-
angiogenic action occurs only when VEGF-A concentrations were low or absent. 
 
4.3.5. Polyphenols modulated VEGF-B signaling and PFKFB3 glycolysis regulator in 
diabetic mice 
As depicted in Figure 4.6, diabetic animals exhibited an increase VEGFR-1 and its co-
receptor NP-1 expression in kidney and left ventricle, as well as in VEGF-B (Figure 4.3). VEGF-B 
binds to VEGFR-1 and NP-1, controlling lipid transport and peripheral tissues uptake (Hagberg 
et al., 2010; Hagberg et al., 2013). Diabetic animals consuming XN and 8PN, the expression of 
VEGFR-1 is significantly reduced for both beer polyphenols in kidney (1.41±0.2 for XN and 
1.29±0.1 for 8PN) and left ventricle (0.69±0.1 for mice treated with XN and 0.92±0.1 for 8PN), 
when compared to DM-Ethanol (2.06±0.1 in kidney and 1.70±0.1 in left ventricle) (Figure 4.6 A, 
D, G, H). NP-1 was also reduced upon treatment of XN (0.73±0.2 in kidney and 0.72±0.1 in left 
ventricle) and there is a tendency towards reduction for 8PN consumption (0.77±0.1 in kidney 
and 0.83±0.1 in left ventricle), when compared to DM-Ethanol (1.10±0.2 in kidney and 
1.17±0.1 in left ventricle). 
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Since metabolism also mediates angiogenesis, the influence of polyphenols in PFKFB3 
expression, an enzyme that enhances glycolysis when the angiogenic process is activated, was 
evaluated. Interestingly, as shown in Figure 4.5 C and F, PFKFB3 expression profile was 
identical to the angiogenic receptor pathway expression observed (Figure 4.4). PFKFB3 
expression was increased in kidney of diabetic animals (2.03±0.2 and 1.92±0.3, in DM and DM-
Ethanol groups respectively) when compared to healthy control (1.34±0.2). This was prevented 
after XN (1.36±0.1) and 8PN (1.4±0.2) oral administration. Inversely, the expression of this 
glycolytic activator is downregulated in left ventricle in diabetic animals (0.78±0.1) when 
compared to healthy control mice (1.68±0.1). XN (1.31±0.2) and 8PN (1.35±0.1) consumption 
Figure 4.6 - Expression of VEGFR-1, NP-1, and PFKFB3 enzyme in kidney (A-C) and left ventricle (D-F) of healthy and 
T2DM animals subjected to distinct treatments during 20 weeks. A representative Western blotting is shown from three 
independent experiments (G and H). Control, healthy (standard diet-fed) mice; DM, diabetic animals (fed with HFD); 
DM-Ethanol, diabetic animals drinking 0.1 % ethanol; DM-XN, diabetic animals treated with 10 mg/L XN; DM-8PN, 
diabetic animals consuming 10 mg/L 8PN. Results are expressed as means ± SD (5<n<6). *p ≤ 0.05 vs control; # p ≤ 
0.05 vs DM; δ p ≤ 0.05 vs DM-Ethanol, γ p ≤ 0.05 vs DM-XN. 
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reversed this effect as shown by the significant increase in PFKFB3 expression in comparison to 
their ethanol control group (0.79±0.1). 
 
4.4. Discussion 
Diabetes-associated vascular complications are highly dependent on organ-specific 
metabolic disturbances. We addressed the interplay between angiogenesis and metabolism, 
by examining two organs that display increased (kidney) and impaired (left ventricle) 
vascularization in T2DM mice fed during 20 weeks with a HFD. Diabetic mice exhibit increased 
body weight gain and sustained elevated glycemia levels without affecting the amount of food 
and beverage intake per body weight throughout the study. We showed that oral 
administration of XN and 8PN lowered blood glucose in diet-induced diabetic mice, improving 
T2DM conditions. Corroborating our data, there is growing experimental and epidemiological 
evidence that XN aside from the antioxidant properties, also plays anti-hyperglycemic and anti-
diabetes roles (Legette et al., 2013; Yui et al., 2014). But to our knowledge, the effect of 8PN in 
body weight gain and glycemia in diabetic animals has never been reported before. 
The most devastating consequences of diabetes arise from the microvascular 
complications associated with nephropathy, neuropathy and retinopathy. In agreement with 
the literature, our results confirm the existence of an angiogenic paradox in diabetic animals 
(Wirostko et al., 2008). As illustrated in Figure 4.7, an increase in renal neovascularization and 
an impairment of blood vessel growth in left ventricle assessed by immunohistochemistry 
stained for the endothelial marker CD31, and corroborated by Western blotting analyses for 
phospho-VEGFR-2 and downstream effectors, and VEGF-A by ELISA was observed. According to 
our results, VEGF-A up-regulation in diabetic kidney binds and activates VEGFR-2 in EC, 
resulting in increased ERK and AKT MAPK downstream effector signaling. This whole 
mechanism leads to augmented microvessel density. MAPK directly up-regulates pro-
 Modulation of VEGF signaling in a mouse model of diabetes by xanthohumol and 8-prenylnaringenin: 
Unveiling the angiogenic paradox and metabolism interplay 
 
 
 70 
inflammatory mediators such as IL-1 and NF-κB (Kerimi et al., 2016) that are augmented in 
T2DM. In contrast, these animals exhibit a reduction in the number of vessels in left ventricle, 
which can be explained by the decreased VEGF-A levels and VEGFR-2 signaling pathway 
impairment. Circulating VEGF-A levels in these experimental groups are decreased in 
accordance to other studies (Carneiro et al., 2012; Zakareia, 2012; Costa et al., 2013), but this 
systemic biomarker is a poor angiogenesis indicator, as the systemic levels did not correspond 
to the ones quantified in organs from T2DM animals (Figure 4.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In accordance with our previous studies, the current study demonstrated that XN exhibit 
an anti-angiogenic potential, especially in the kidney, where it significantly reduced VEGF-A 
levels, VEGFR-2 activation, and microvessel density. 8PN ameliorate the angiogenic paradox as 
Figure 4.7 - Schematic representation of the angiogenic paradox in HFD-fed mice and its modulation upon XN and 8PN 
consumption. XN consumption prevents the augment in kidney neovascularization assessed by the VEGF-A levels, 
VEGFR-2 and downstream signal activation (ERK 42/44 and AKT effectors) and the microvascular density in T2DM-
induced mice. 8PN consumption activates the angiogenic process which is impaired in left ventricle of T2DM-induced 
mice with lower levels of VEGF-A, expression of VEGFR-2 and downstream effectors (ERK 42/44 and AKT) and 
reduced number of vessels. 
 
Modulation of VEGF signaling in a mouse model of diabetes by xanthohumol and 8-prenylnaringenin: 
Unveiling the angiogenic paradox and metabolism interplay 
 
 
 71 
well, enhancing VEGF-A in diabetic left ventricle where angiogenesis is impaired in T2DM. 
Corroborating these findings, Yoon and collaborators demonstrate cardio-protective effects in 
diabetic mice after injection of a plasmid encoding VEGF-A, restoring microvascular 
homeostasis by improving angiogenic signaling (Yoon et al., 2005). Our group already pointed 
out 8PN as a pro-angiogenic molecule in diabetic animals (Negrão et al., 2010), possibly due to 
its estrogen agonist properties, already established as angiogenic promoter (Soares, Guo, 
Gartner, et al., 2003; Soares, Guo, Russo, et al., 2003), 
Interestingly, 8PN led to an augmented VEGF-A serum and left ventricle levels without any 
significant effect on this growth factor in kidney. Interestingly, despite the opposite effect of 
both polyphenols concerning angiogenic process, in kidney, 8PN also down-regulates ERK 
phosphorylation possibly leading to a more controlled endothelial proliferation. In turn, XN up-
regulates AKT in left ventricle to levels similar to healthy mice, playing thus a role in survival 
and also in the insulin signaling cascade by stimulating glucose uptake (Konner et al., 2012). 
These results suggest that other pathways must be regulated, contributing to the mentioned 
effects due to the pleiotropic action of polyphenols.  
Previous experiments indicated that specific polyphenols inhibit VEGF-induced activation 
of VEGFR-2 by direct binding to VEGF-A (Cerezo et al., 2015; Moyle et al., 2015). Our cell 
culture assays show that inhibition of VEGF-induced VEGFR-2 phosphorylation by XN was 
remarkably increased upon co-incubation of this compound with VEGF-A.  
On the other hand, 8PN treatment leads to a significant activation of VEGFR-2 but it only 
occurs on HMEC-1 without stimulation. These findings suggest that these two polyphenols 
differently affected VEGFR-2 phosphorylation depending on tissue VEGF-A content. For 
instance, in kidney from T2DM mice, with increased VEGF-A levels, XN was able to reduce 
angiogenic process. On the other hand, in left ventricle where angiogenesis is impaired, 8PN 
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was able to increase angiogenesis. The low VEGF-A levels in this tissue could explain this effect, 
since 8PN in vitro led to a significant VEGFR-2 activation only in the absence of VEGF-A.  
A considerable body of evidence indicates that hyperglycemia and associated 
comorbidities affects EC metabolism. In obesity, the excessive FFA are initially stored in 
subcutaneous adipose tissue, but once that capacity is reached, they are ectopically 
accumulated in peripheral tissues and vasculature, leading to lipotoxicity, increased 
inflammation and immune system activation (Heilbronn et al., 2004; Costanzo et al., 2015). In 
the current work, VEGF-B and its receptors are overexpressed in HFD-fed animal’s kidney and 
left ventricle. For the first time, our results showed that XN and 8PN modulate the VEGF-
VEGFR-1 pathway to healthy controls levels. Other authors demonstrated that when VEGF-B 
binds to VEGFR-1 and NP-1, the vascular expression of FATP-3 and FATP-4 is increased through 
a PI3K-dependent pathway (Hagberg et al., 2010), and also by estrogen-related receptor alpha 
and peroxisome proliferator-activated receptor gamma coactivator 1- alpha induced by AMPK 
(Villena et al., 2008). Taking these findings into account, our results suggest that both XN and 
8PN can be promising agents against pathological lipid accumulation, a characteristic of T2DM 
patients.  
Moreover, the carbohydrate metabolism was also highlighted in the current study. PFKFB3 
is a glycolysis activator present in active EC (De Bock et al., 2013). Accordingly, the expression 
profile of this enzyme accompanied the vascular profile, as diabetic mice presented increased 
PFKFB3 expression in kidney and reduced in left ventricle. By inducing fructose-2,6-
bisphosphate, an allosteric effector of primary control point of glycolysis, PFKFB3 enzyme 
enhances ATP synthesis, a mainstay for EC growth and migration activity (De Bock et al., 2013). 
Remarkably, both XN and 8PN attenuated these effects into healthy control values, implying 
that these compounds also normalized carbohydrate metabolism in vascular endothelium. 
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Altogether, we demonstrated that XN and 8PN, in a dose of 1 mg/kg body weight/day, 
reduce diet-induced obesity and diabetes by modulating angiogenesis and metabolic 
parameters. In addition to well-documented health-promoting effects of polyphenols, the 
present work demonstrated that both XN and 8PN, possess positive effects on the HFD-fed 
animal’s heart and kidney, ameliorating the angiogenic paradox as illustrated in Figure 4.7. We 
further described for the first time target molecules mediating its biological actions, including 
the modulation of glycolytic enzyme PFKFB3 that mediates vessel sprouting and VEGF-B 
signaling pathway that mediates cellular responses involved in the lipid transport in EC and 
uptake by peripheral tissues.  
Although additional research is needed to better understand the interplay between 
angiogenesis and metabolism, our findings suggest that beer-derived polyphenols prevent 
angiogenic impairment and metabolic pathways that are implicated in the pathogenesis of 
T2DM, being promising compounds to mitigate the increasing number of diabetic patients and 
inherent health care costs. 
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General discussion 
 
During the last decades many efforts have been made to identify and develop novel 
therapeutic strategies for the management of T2DM. However, the current therapies are not 
entirely sufficient to maintain sustained glycemic control. Moreover, generalized unhealthy 
dietary habits and sedentary life style of the western population, contributes to the rising 
incidence of T2DM, a major public health problem. It is therefore critical to identify new 
molecular targets in T2DM and to develop new therapeutic approaches that prevent and 
control T2DM progression. Natural compounds, as polyphenols, are attractive alternatives to 
prevent the development of T2DM and accompanying cardiovascular disease. 
The present study aimed to investigate the potential role of the XN and 8PN polyphenols 
as modifiers of T2DM physiopathology, using a murine model of HFD-induced T2DM. 
Specifically, this work explored how XN and 8PN modulate fundamental molecular 
mechanisms and signaling pathways involved in the development of T2DM and related 
comorbidities, including metabolic deregulation and vascular deregulation.  
The liver is a central organ responsible for whole-body energy metabolism and nutrient 
homeostasis and the skeletal muscle is an important site for insulin action. Therefore, we 
focused in these two organs in order to examine the effect of these polyphenols in T2DM 
metabolism. Consumption of XN or 8PN improved glycemic control as demonstrated by the 
reduction of glycemia and insulin levels, HOMA and QUICKI, when compared to untreated 
HFD-fed animals. The improvement of insulin sensitivity could be one of the underlying 
mechanisms by which both polyphenols reduce the body weight gain during the 20 weeks of 
intervention. This effect has also been reported by other authors (Kim, Keogh, et al., 2016). 
Corroborating our data, there is growing experimental and epidemiological evidence that 
XN, aside from the antioxidant properties, also plays anti-hyperglycemic and antidiabetic roles 
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(Legette et al., 2013; Yui et al., 2014). But to our knowledge, the effect of 8PN in body weight 
gain, glycemia and lipid-lowering capacity has never been reported before. 
The present study showed that both XN and 8PN significantly reduced plasma total 
cholesterol and TG that were elevated after a HFD regimen. These lipid-lowering effects upon 
oral administration of XN and 8PN could be partially attributable to an inhibition of lipid 
absorption in the gut, a decrease of FA synthesis, a reduction in the synthesis of cholesterol, an 
alteration in the metabolism of lipoproteins or an increase of FA oxidation, among other 
possible mechanisms. In order to better understand whether XN and 8PN improve metabolic 
parameters, the expression of enzymes that regulate lipid and glucose metabolism was also 
evaluated together with the energy metabolism master regulator, AMPK. Importantly, several 
pharmacological agents used to treat T2DM are powerful inducers of AMPK as for instance, 
insulin-sensitizing activators of PPAR-γ drugs from the thiazolidinedione family, hypoglycemia 
drug metformin, GLP1 agonists, and DPP4 inhibitors, demonstrating its ability on the 
prevention of T2DM (Hardie, 2013; Coughlan et al., 2014; Kim, Yang, et al., 2016; Tahrani et al., 
2016). We observed that both polyphenols were able to counteract the reduction of AMPK 
expression caused by HFD in liver and skeletal muscle tissues. The polyphenol-induced 
activation of AMPK led to a decrease of the expression of the downstream effector SREBP-1c 
and its target proteins, ACC and FAS. ACC down-regulation led to a decline in the flow of acetyl 
CoA to malonyl-CoA, the precursor of FA synthesis. This probably resulted in CPT-1 inhibition 
release, promoting the transfer of cytosolic long-chain fatty acyl CoA into the mitochondria to 
undergo -oxidation. The reduction in FAS expression has already been described for other 
polyphenols and reported as a potential target to treat obesity, metabolic syndrome and 
cancer, conditions in which this enzyme is over-expressed (Tian, 2006).  
Polyphenols consumption was also able to improve the plasmatic lipid profile, reduce the 
hepatic and skeletal muscle TG and cholesterol content and decrease the lipid uptake. The 
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tissue uptake of FA is mediated by several facilitated transporters as the CD36, which is 
upregulated in obesity (Goldberg et al., 2009). Interestingly, the expression of CD36 in HFD-fed 
animals was reduced and normalized after XN or 8PN consumption. This could be, therefore, 
one of the mechanisms responsible for the reduction of hepatic and muscular lipid 
accumulation after polyphenol treatment. Additionally, both polyphenols also modulate the 
VEGFR-1-VEGF-B axis. VEGF-B levels and the expression of its receptor VEGFR-1 and co-
receptor NP-1 in the liver and skeletal muscle were all decreased in HFD-fed animals treated 
with polyphenols. As this pathway has been recently associated with the expression of FATP 
(Hagberg et al., 2010), the down-regulation of this signaling pathway suggests that this could 
be another mechanism by which these polyphenols may prevent ectopic lipid accumulation 
within these tissues. Other authors have previously demonstrated that VEGF-B does not affect 
CD36 expression (Hagberg et al., 2010), leading us to hypothesize that the expression of 
VEGFR-1-VEGF-B axis and CD36 transporter are independently players down-regulated by XN 
and 8PN in T2DM. These results are in agreement with studies testing other polyphenols, 
namely grape extract-derived polyphenols, that significantly reduce CD36-mediated lipid 
transport and increase GLUT-4 expression in the skeletal muscle of high fat and high sucrose 
diet-fed rats (Aoun et al., 2011).  
The associated T2DM-related comorbidities also affect the metabolism of EC. In an attempt 
to give new insights in the interplay between metabolism and angiogenesis we evaluated the 
VEGFR-1-VEGF-B axis in the kidney and in the left heart ventricle. We decided to focus in these 
two organs because in T2DM, angiogenesis is paradoxically increased in the kidney and 
reduced in the left ventricle, contributing to diabetic nephropathy and heart failure, 
respectively. This is the so called diabetic angiogenic paradox (Wirostko et al., 2008; 
Waltenberger, 2009). We observed that both XN and 8PN were also able to counteract the 
increase of VEGF-B levels and the expression of VEGFR-1 and NP-1, observed in the kidney and 
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left ventricle of HFD-fed animals. Our results showed that both polyphenols modulate the 
VEGF-VEGFR-1 pathway, decreasing its signalization. Other authors demonstrated that the 
activation of this signaling pathway leads to the upregulation of FATP-3 and FATP-4 through a 
PI3K-dependent pathway promoting the endothelial-to-tissues lipid transport (Hagberg et al., 
2010). Blocking VEGF-B signaling has attracted considerable attention in metabolic diseases, as 
it may prevent ectopic lipid accumulation and restore insulin sensitivity in obesity and T2DM 
animal models (Carmeliet et al., 2012; Hagberg et al., 2013; Muhl et al., 2016).  
Moreover, XN and 8PN were also able to ameliorate glucose homeostasis as demonstrated 
by the decrease in plasma glucose levels and HOMA results. This could be related to the 
observed increase in AS160 expression in skeletal muscle. AS160 phosphorylation is related to 
the translocation of GLUT-4 to the cell membrane and subsequent increase of glucose uptake 
by the skeletal muscle (Klip, 2009). Furthermore, XN and 8PN also modulated the expression of 
PFKFB3, an important glycolytic regulator involved in insulin signaling (Trefely et al., 2015), in 
liver and skeletal muscle. This suggests that the observed polyphenol-induced activation of 
PFKFB3 may promote glycolysis together with glucose uptake in the skeletal muscle. Apart 
from its metabolic role, PFKFB3 was also recently found to regulate angiogenesis (Cantelmo et 
al., 2015). It was shown that during angiogenesis, EC rely on glycolysis for rapid energy 
generation to proliferate and migrate towards avascular areas. In this process, endothelial 
PFKFB3 is a key player (Cantelmo et al., 2015). Therefore, we pinpointed the linkage between 
metabolism and angiogenesis mediated by PFKFB3 in T2DM and questioned whether XN and 
8PN could modulate PFKFB3. Indeed, our results demonstrate that PFKFB3 is increased in the 
kidney and decreased in left ventricle in HFD-fed animals and that remarkably, both XN and 
8PN were able to attenuate this imbalance to levels similar to those presented by healthy 
control group, controlling vascular growth. The results are in agreement with Shoors and co-
authors that have demonstrated that when PFKFB3 is silenced in vitro or inactivated in vivo, 
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glycolysis becomes partially and transiently suppressed and angiogenesis impaired inducing 
endothelial cell quiescence (Schoors, De Bock, et al., 2014). Accordingly, the expression profile 
of this enzyme accompanied the angiogenic pattern observed in the diabetic kidney and left 
ventricle. Understanding the vascular imbalance observed in distinct organs in diabetes may 
provide a mean to therapeutically modulate neovascular events with precision in diabetes. 
Moreover, we confirmed an increase in renal neovascularization and an impairment of 
angiogenesis in left ventricle of HFD-fed animals, assessed by the expression of endothelial 
marker CD31 and VEGFR-2-VEGF-A axis and downstream effectors. This results in an 
augmented microvessel density. In contrast, these animals exhibit a reduction in the number 
of vessels in the left ventricle, which can be explained by decreased levels of VEGF-A and by an 
impairment of the VEGFR-2 signaling pathway. In accordance with our previous studies 
(Negrão et al., 2010; Negrão et al., 2012; Costa et al., 2013), the current study demonstrates 
that XN has an anti-angiogenic potential, especially in the kidney. Contrarily, 8PN enhances 
VEGF-A in the diabetic left ventricle where angiogenesis is impaired, without significant effect 
in kidney, therefore ameliorating the angiogenic paradox as well. Our group had previously 
shown that in diabetic animals, 8PN is a pro-angiogenic molecule (Negrão et al., 2010), 
possibly due to its estrogen agonist properties, which are known to promote angiogenesis 
(Soares, Guo, Gartner, et al., 2003; Soares, Guo, Russo, et al., 2003). 
Interestingly, despite the apparently opposing angiogenic effects of both polyphenols in 
kidney, 8PN also down-regulates ERK phosphorylation possibly leading to a more controlled 
endothelial proliferation. Also, XN up-regulates AKT in the left ventricle to levels similar to 
healthy mice, therefore playing a role in cell survival and in the stimulation of insulin signaling 
and glucose uptake (Konner et al., 2012). These intriguing results led us to investigate the 
effect of each polyphenol on the VEGF-induced activation of VEGFR-2 in an EC culture, 
subjected to hyperglycemic conditions. Several studies reported that the angiogenic behavior 
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of some polyphenols was mediated by direct binding to VEGF-A (Cerezo et al., 2015; Moyle et 
al., 2015). In agreement, it was demonstrated that XN when co-incubated with VEGF-A led to 
an increase inhibition of VEGF-induced VEGFR-2 phosphorylation. In contrast, when EC are 
treated with 8PN there is an activation of VEGFR-2 only in the absence of VEGF-A. XN and 8PN 
seemed to distinctly affect VEGFR-2 activation depending on the tissue VEGF-A content. While 
XN counteracted the increase of angiogenesis in the kidney mediated by HFD consumption, 
8PN increased vascularization of the left ventricle, where angiogenesis was impaired. The low 
VEGF-A levels in this tissue could explain this effect, since 8PN promotes the in vitro activation 
of VEGFR-2 only in the absence of VEGF-A.  
Despite the well-recognized benefits of daily consumption of fruits and vegetables, the 
daily dietary intake of polyphenols in Europe is below the recommended to obtain a significant 
health-promoting effect (Vogiatzoglou et al., 2015). In recent years, the production of 
polyphenol-enriched foods and beverages becomes a challenge to increase polyphenol 
consumption. The dietary intake of XN and 8PN only occurs upon beer ingestion, and several 
studies concerning pharmacokinetics and tissue distribution of these compounds were 
recently carried out. In the present thesis, the administered dose of XN and 8PN was 10 mg/L, 
which is equivalent to 1.0 mg/kg body weight/day in mice, in line with our previous studies 
(Negrão et al., 2012; Costa et al., 2013). The administered doses that attain health benefits are 
not reached by beer consumption alone emphasizing the importance of supplemented 
beverages that are already being produced by the brewing industry 
Leggete and collaborators tested oral administration of XN in a dose of 16.9 mg/kg body 
weight that corresponds to 180 mg for 66 kg of body weight in humans, and demonstrated 
that it appears in the plasma 4 hours post-administration in a concentration of 0.37 μM after 
intestinal absorption and enterohepatic recirculation. XN isomerization increases the 
concentration of IXN reaching a peak around 7-8 hours and 8PN only reached the peak 
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concentration at 15-24 hours due to the hepatic demethylation of IXN into 8PN (Legette et al., 
2012).. Later, the same authors described an improvement of DNA stability and health-related 
biochemical markers after a daily oral consumption of a XN drink or XN pills both with 12 mg/L, 
reaching 6.13 ng XN/mL in plasma 4 hours after administration (Legette et al., 2014). Recently, 
in an interesting study in animals fed with a HFD mixed with 60 mg XN/kg body weight/day, a 
dose that corresponds to 350 mg/kg body weight/day in humans, Miranda C and co-authors 
demonstrated the anti-obesity capacity of XN by a decrease in body weight, inflammatory 
mediators and biochemical markers, implicated in insulin resistance of T2DM (Miranda et al., 
2016a). 8PN was quantified in the plasma after in vivo XN metabolization (Legette et al., 2012), 
but animal and human studies focusing the non-estrogenic effects of 8PN are scarce. For the 
first time, the current study reports the effect of 8PN in T2DM.  
The study of molecular mechanisms leads to the identification of new molecular targets for 
XN and 8PN intake. Despite the similar chemical structure, XN and 8PN display opposite effects 
on angiogenic process and on the regulation of PFKFB3. This cross-talk between metabolism 
and angiogenesis emerges as an important therapeutic target. New perspectives have arisen 
regarding the health benefits of polyphenols as promising tissue-specific preventive 
approaches to ameliorate T2DM-related complications and improve the quality of life of 
diabetic patients. 
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Final remarks and future work 
 
The present thesis aimed to explore the potential role of two beer-derived polyphenols, XN 
and 8PN, in the prevention of metabolic and vascular T2DM-related complications in a HFD-
induced T2DM mice model. A particular focus was given to the modulation of fundamental 
molecular pathways implicated in T2DM deregulation by these polyphenols. The main 
conclusions of this work are: 
XN and 8PN reduced body weight gain and maintained glucose homeostasis in a HFD-
diabetes induced in vivo model. This was achieved by a reduction of hyperglycemia, an 
improvement in HOMA index and an increase in insulin sensibility, in part as a result of the 
modulation of glycolytic pathway through PFKFB3 regulation;  
XN and 8PN demonstrated a lipid-lowering effect through the reduction of blood TG and 
cholesterol, a decrease in lipid transport from the endothelium to tissues, and a reduction of 
lipogenic enzymes expression, therefore preventing lipotoxicity. Importantly, AMPK/SREBP-1c 
and target enzymes ACC and FAS, CD36 and VEGFR-1/VEGF-B were identified as targets for 
these polyphenols; 
XN and 8PN seemed to modulate angiogenesis selectively, according to the VEGF-A 
concentration in the surrounded microenvironment. This observation suggests that both 
polyphenols can be used as tissue-specific therapies to resolve the so-called angiogenic 
paradox.  
The presented data unravel new insights in the interesting inter-relation between 
metabolism and angiogenesis, and its modulation by dietary polyphenols rendering them 
potential preventive approaches for T2DM-related complications. 
The work developed in this thesis provides interesting new findings but also opens new 
questions and suggests future experiments that address the proper scientific validation to 
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attain safety and efficacy of optimal polyphenols doses. It is also important to discard any 
possible side effects of their consumption especially regarding the less studied 8PN 
consumption, which could have undesirable effects mediated by its proestrogenic properties. 
Clinical trials are also needed to assess the optimal dosage and formulation for both 
compounds delivery, since the inter-individual variations and gut composition alters the 
polyphenols bioavailability and the nutritional-drug interactions.  
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